Reversal of Cancer Cachexia and Muscle Wasting by Act
Prolonged Survival

Cell

142, 531-543

DOI: 10.1016/j.cell.2010.07.011

Citation Report

#	Article	IF	Citations
3	Preventing wastage. Nature Reviews Drug Discovery, 2010, 9, 763-763.	21.5	4
4	Acceleron and Shire to target the activin receptor pathway for muscular disorders. Nature Reviews Drug Discovery, 2010, 9, 830-830.	21.5	0
6	Reversing Cachexia. Cell, 2010, 142, 511-512.	13.5	48
7	Activation of nuclear factorâ€ÎºB following muscle eccentric contractions in humans is localized primarily to skeletal muscleâ€residing pericytes. FASEB Journal, 2011, 25, 2956-2966.	0.2	54
8	Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response. Nature Communications, 2011, 2, 576.	5.8	52
9	Cancer Cachexia and Fatâ€"Muscle Physiology. New England Journal of Medicine, 2011, 365, 565-567.	13.9	127
10	Role of TGF-Î² signaling in inherited and acquired myopathies. Skeletal Muscle, 2011, 1, 19.	1.9	189
11	Treating cancer cachexia to treat cancer. Skeletal Muscle, 2011, 1, 2.	1.9	44
12	Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skeletal Muscle, 2011, 1, 4.	1.9	558
13	Proteolysis in illness-associated skeletal muscle atrophy: from pathways to networks. Critical Reviews in Clinical Laboratory Sciences, 2011, 48, 49-70.	2.7	62
14	Oral Resveratrol Therapy Inhibits Cancer-Induced Skeletal Muscle and Cardiac Atrophy In Vivo. Nutrition and Cancer, 2011, 63, 749-762.	0.9	82
15	mRNA Expression Signatures of Human Skeletal Muscle Atrophy Identify a Natural Compound that Increases Muscle Mass. Cell Metabolism, 2011, 13, 627-638.	7.2	298
16	Adipose Triglyceride Lipase Contributes to Cancer-Associated Cachexia. Science, 2011, 333, 233-238.	6.0	475
17	Chronic inflammatory states: their relationship to cancer prognosis and symptoms. Journal of the Royal College of Physicians of Edinburgh, The, 2011, 41, 246-253.	0.2	18
18	Hypothalamic regulation of muscle metabolism. Current Opinion in Clinical Nutrition and Metabolic Care, 2011, 14, 237-242.	1.3	15
19	Structures of TGF-β Receptor Complexes: Implications for Function and Therapeutic Intervention Using Ligand Traps. Current Pharmaceutical Biotechnology, 2011, 12, 2081-2098.	0.9	18
20	DÃ©nutrition cancÃ©reuse et inflammation : effet des acides gras polyinsaturÃ©s n-3. Oleagineux Corps Gras Lipides, 2011, 18, 34-38.	0.2	0
21	Inhibin-Î± subunit in normal and malignant human cervical tissue and cervical cancer cell lines. Oncology Reports, 2011, 26, 887-91.	1.2	1

#	Article	IF	Citations
22	Acute antibody-directed myostatin inhibition attenuates disuse muscle atrophy and weakness in mice. Journal of Applied Physiology, 2011, 110, 1065-1072.	1.2	45
24	Beyond anorexia -cachexia. Nutrition and modulation of cancer patients' metabolism: Supplementary, complementary or alternative anti-neoplastic therapy?. European Journal of Pharmacology, 2011, 668, S87-S90.	1.7	24
25	Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein. FEBS Letters, 2011, 585, 1147-1152.	1.3	103
27	Melanocortin system in cancer-related cachexia. Open Medicine (Poland), 2011, 6, 550-557.	0.6	0
28	Tumorâ€"stromal interactions of the bone microenvironment: in vitro findings and potential in vivo relevance in metastatic lung cancer models. Clinical and Experimental Metastasis, 2011, 28, 779-791.	1.7	17
30	IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 105-109.	2.9	50
31	The role of myostatin in muscle wasting: an overview. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 143-151.	2.9	265
32	Nutritional Interventions for Cancer-Induced Cachexia. Current Problems in Cancer, 2011, 35, 58-90.	1.0	99
33	Myostatin (GDF-8) inhibits chondrogenesis and chondrocyte proliferation<i>in vitro</i>by suppressing Sox-9 expression. Growth Factors, 2011, 29, 253-262.	0.5	31
34	InACTIVatINg cancer cachexia. DMM Disease Models and Mechanisms, 2011, 4, 283-285.	1.2	12
35	Generation of a Specific Activin Antagonist by Modification of the Activin A Propeptide. Endocrinology, 2011, 152, 3758-3768.	1.4	23
37	Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor. Physiological Genomics, 2011, 43, 398-407.	1.0	44
38	Prodomains regulate the synthesis, extracellular localisation and activity of TGF-Î² superfamily ligands. Growth Factors, 2011, 29, 174-186.	0.5	99
39	Central nervous system inflammation induces muscle atrophy via activation of the hypothalamicâ€"pituitaryâ€"adrenal axis. Journal of Experimental Medicine, 2011, 208, 2449-2463.	4.2	162
40	Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB Journal, 2011, 25, 1653-1663.	0.2	255
41	Cancer Causes Cardiac Atrophy and Autophagy in a Sexually Dimorphic Manner. Cancer Research, 2011, 71, 1710-1720.	0.4	173
42	Targeting the myostatin signaling pathway to treat muscle wasting diseases. Current Opinion in Supportive and Palliative Care, 2011, 5, 334-341.	0.5	69
43	Taking pressure off the heart: the ins and outs of atrophic remodelling. Cardiovascular Research, 2011, 90, 243-250.	1.8	48

#	Article	IF	Citations
44	Emerging Roles for the Transforming Growth Factor-Î² Superfamily in Regulating Adiposity and Energy Expenditure. Endocrine Reviews, 2011, 32, 387-403.	8.9	165
45	C/EBPÎ² mediates tumour-induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wasting. EMBO Journal, 2011, 30, 4323-4335.	3.5	114
46	Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H1973-H1982.	1.5	97
47	Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 301, R716-R726.	0.9	97
48	Myostatin promotes the wasting of human myoblast cultures through promoting ubiquitin-proteasome pathway-mediated loss of sarcomeric proteins. American Journal of Physiology - Cell Physiology, 2011, 301, C1316-C1324.	2.1	94
49	Targeting Protein Synthesis in a Myc/mTOR-Driven Model of Anorexia-Cachexia Syndrome Delays Its Onset and Prolongs Survival. Cancer Research, 2012, 72, 747-756.	0.4	34
50	Structural and functional characterizations of activin type 2B receptor (acvr2b) ortholog from the marine fish, gilthead sea bream, Sparus aurata: evidence for gene duplication of acvr2b in fish. Journal of Molecular Endocrinology, 2012, 49, 175-192.	1.1	7
51	The aging myostatin null phenotype: reduced adiposity, cardiac hypertrophy, enhanced cardiac stress response, and sexual dimorphism. Journal of Endocrinology, 2012, 213, 263-275.	1.2	52
52	Translational implications of novel findings in cancer cachexia. Current Opinion in Supportive and Palliative Care, 2012, 6, 446-450.	0.5	11
53	Survival. Current Opinion in Clinical Nutrition and Metabolic Care, 2012, 15, 211-212.	1.3	5
54	The translation inhibitor pateamine A prevents cachexia-induced muscle wasting in mice. Nature Communications, 2012, 3, 896.	5.8	54
55	Editorial update on emerging drugs for cancer cachexia. Expert Opinion on Emerging Drugs, 2012, 17, 5-9.	1.0	12
56	Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. British Journal of Cancer, 2012, 106, 1583-1586.	2.9	97
57	Role of satellite cells versus myofibers in muscle hypertrophy induced by inhibition of the myostatin/activin signaling pathway. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2353-60.	3.3	156
58	Molecular mechanisms of cachexia in chronic disease. Expert Review of Endocrinology and Metabolism, 2012, 7, 73-90.	1.2	2
59	Cancer Cachexia: Molecular Targets and Pathways for Diagnosis and Drug Intervention. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2012, 12, 247-259.	0.6	13
60	Muscle protein kinetics in cancer cachexia. Current Opinion in Supportive and Palliative Care, 2012, 6, 417-423.	0.5	10
61	Myostatin is a novel tumoral factor that induces cancer cachexia. Biochemical Journal, 2012, 446, 23-36.	1.7	85

#	Article	IF	Citations
62	Interference with Myostatin/ActRIIB Signaling as a Therapeutic Strategy for Duchenne Muscular Dystrophy. Current Gene Therapy, 2012, 12, 245-259.	0.9	55
63	Cachexia and Sarcopenia: Emerging Syndromes of Importance in Dogs and Cats. Journal of Veterinary Internal Medicine, 2012, 26, 3-17.	0.6	142
64	Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 37-43.	2.9	115
65	Combined Effect of AAV-U7-Induced Dystrophin Exon Skipping and Soluble Activin Type IIB Receptor in <i>mdx</i> Mice. Human Gene Therapy, 2012, 23, 1269-1279.	1.4	31
66	The skeletal muscle secretome: an emerging player in muscleâ€"bone crosstalk. BoneKEy Reports, 2012, 1, 60.	2.7	109
67	Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin. Journal of Cell Biology, 2012, 197, 997-1008.	2.3	167
68	The bright and the dark sides of activin in wound healing and cancer. Journal of Cell Science, 2012, 125, 3929-37.	1.2	90
69	The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle proteins. EMBO Journal, 2012, 31, 3334-3350.	3.5	78
70	Myostatin inhibition induces muscle fibre hypertrophy prior to satellite cell activation. Journal of Physiology, 2012, 590, 2151-2165.	1.3	102
71	Expression of myeloid differentiation factor 88 in neurons is not requisite for the induction of sickness behavior by interleukin-1Î². Journal of Neuroinflammation, 2012, 9, 229.	3.1	26
72	Se-Jin Lee, myostatin discoverer, elected to the National Academy of Science. Skeletal Muscle, 2012, 2, 11.	1.9	1
73	Cardiac Plasticity in Health and Disease. , 2012, , 185-250.		1
74	Connexin- and Pannexin-Based Channels in Normal Skeletal Muscles and Their Possible Role in Muscle Atrophy. Journal of Membrane Biology, 2012, 245, 423-436.	1.0	37
75	Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways. Cell Metabolism, 2012, 16, 153-166.	7.2	931
77	Lost in translation: regulation of skeletal muscle protein synthesis. Current Opinion in Pharmacology, 2012, 12, 377-382.	1.7	37
78	Identification of decorin derived peptides with a zinc dependent anti-myostatin activity. Neuromuscular Disorders, 2012, 22, 1057-1068.	0.3	16
79	Can cancer cachexia be prevented/treated?. Nutrition, 2012, 28, 844-848.	1.1	3
81	The 2011 ESPEN Arvid Wretlind lecture: Cancer cachexia: The potential impact of translational research on patient-focused outcomes. Clinical Nutrition, 2012, 31, 577-582.	2.3	43

#	Article	IF	Citations
82	Myostatin. , 2012, , 1077-1084.		9
83	Identification of atrogin-1-targeted proteins during the myostatin-induced skeletal muscle wasting. American Journal of Physiology - Cell Physiology, 2012, 303, C512-C529.	2.1	90
84	Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 77-94.	2.9	103
85	Myostatin: more than just a regulator of muscle mass. Drug Discovery Today, 2012, 17, 702-709.	3.2	105
86	Muscle wasting in animal models of severe illness. International Journal of Experimental Pathology, 2012, 93, 157-171.	0.6	49
87	New insights into the mechanisms of activin action and inhibition. Molecular and Cellular Endocrinology, 2012, 359, 2-12.	1.6	81
88	Mutations in inhibin and activin genes associated with human disease. Molecular and Cellular Endocrinology, 2012, 359, 113-120.	1.6	14
89	Activins and inhibins in mammalian testis development: New models, new insights. Molecular and Cellular Endocrinology, 2012, 359, 66-77.	1.6	43
90	Production of bioactive extracellular domain of pig and chicken activin type IIB receptors in Pichia pastoris. Process Biochemistry, 2012, 47, 139-146.	1.8	5
91	Candidate mechanisms underlying effects of contractile activity on muscle morphology and energetics in cancer cachexia. European Journal of Cancer Care, 2012, 21, 143-157.	0.7	21
92	Inhibition of myostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice. Diabetologia, 2012, 55, 183-193.	2.9	154
93	Building muscle, browning fat and preventing obesity by inhibiting myostatin. Diabetologia, 2012, 55, 13-17.	2.9	38
94	Mechanisms stimulating muscle wasting in chronic kidney disease: the roles of the ubiquitin-proteasome system and myostatin. Clinical and Experimental Nephrology, 2013, 17, 174-182.	0.7	42
95	Myostatin/activin pathway antagonism: Molecular basis and therapeutic potential. International Journal of Biochemistry and Cell Biology, 2013, 45, 2333-2347.	1.2	232
96	Cachexia in chronic heart failure: endocrine determinants and treatment perspectives. Endocrine, 2013, 43, 253-265.	1.1	15
97	MG132-mediated inhibition of the ubiquitinâ€"proteasome pathway ameliorates cancer cachexia. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1105-1115.	1.2	53
98	Î²2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders. International Journal of Biochemistry and Cell Biology, 2013, 45, 2309-2321.	1.2	64
99	The influence of skeletal muscle on systemic aging and lifespan. Aging Cell, 2013, 12, 943-949.	3.0	179

#	Article	IF	Citations
100	Control of food intake and muscle wasting in cachexia. International Journal of Biochemistry and Cell Biology, 2013, 45, 2179-2185.	1.2	48
101	The therapeutic potential of IGF-I in skeletal muscle repair. Trends in Endocrinology and Metabolism, 2013, 24, 310-319.	3.1	69
102	Stat3 Activation Links a C/EBPÎ´ to Myostatin Pathway to Stimulate Loss of Muscle Mass. Cell Metabolism, 2013, 18, 368-379.	7.2	211
104	Muscle wasting in cancer. International Journal of Biochemistry and Cell Biology, 2013, 45, 2215-2229.	1.2	154
105	Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem. Trends in Endocrinology and Metabolism, 2013, 24, 174-183.	3.1	124
106	The regulation of muscle protein turnover in diabetes. International Journal of Biochemistry and Cell Biology, 2013, 45, 2239-2244.	1.2	36
107	Metabolic targets for cancer therapy. Nature Reviews Drug Discovery, 2013, 12, 829-846.	21.5	592
108	Recent progress in elucidating signalling proteolytic pathways in muscle wasting: Potential clinical implications. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, S1-S5.	1.1	9
109	SIRT1 Protein, by Blocking the Activities of Transcription Factors FoxO1 and FoxO3, Inhibits Muscle Atrophy and Promotes Muscle Growth. Journal of Biological Chemistry, 2013, 288, 30515-30526.	1.6	160
110	The Influence of Kidney Disease on Protein and Amino Acid Metabolism. , 2013, , 1-16.		1
111	Phospholipase D regulates the size of skeletal muscle cells through the activation of mTOR signaling. Cell Communication and Signaling, 2013, 11, 55.	2.7	34
112	Activinâ€Î²_c reduces reproductive tumour progression and abolishes cancerâ€associated cachexia in inhibinâ€deficient mice. Journal of Pathology, 2013, 229, 599-607.	2.1	29
113	Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking of myostatin and activins. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E41-E50.	1.8	76
114	Understanding the mechanisms and treatment options in cancer cachexia. Nature Reviews Clinical Oncology, 2013, 10, 90-99.	12.5	729
116	Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia. International Journal of Cardiology, 2013, 168, 3412-3418.	0.8	46
117	Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia. International Journal of Cardiology, 2013, 170, 160-166.	0.8	28
118	The activins and their binding protein, follistatinâ€"Diagnostic and therapeutic targets in inflammatory disease and fibrosis. Cytokine and Growth Factor Reviews, 2013, 24, 285-295.	3.2	111
119	The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy. International Journal of Cardiology, 2013, 168, 3527-3531.	0.8	37

#	Article	IF	Citations
120	Role of satellite cells in muscle growth and maintenance of muscle mass. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, S12-S18.	1.1	121
121	Mechanisms regulating skeletal muscle growth and atrophy. FEBS Journal, 2013, 280, 4294-4314.	2.2	1,115
122	Beyond TGFÎ²: roles of other TGFÎ² superfamily members in cancer. Nature Reviews Cancer, 2013, 13, 328-341.	12.8	352
123	Bladder cancer-induced skeletal muscle wasting: Disclosing the role of mitochondria plasticity. International Journal of Biochemistry and Cell Biology, 2013, 45, 1399-1409.	1.2	54
124	Activin, neutrophils, and inflammation: just coincidence?. Seminars in Immunopathology, 2013, 35, 481-499.	2.8	42
125	The therapeutic potential of blocking the activin signalling pathway. Cytokine and Growth Factor Reviews, 2013, 24, 477-484.	3.2	21
126	Growth Differentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy. Cell, 2013, 153, 828-839.	13.5	791
127	Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. International Journal of Cardiology, 2013, 162, 73-76.	0.8	23
128	A single ascendingâ€dose study of muscle regulator aceâ€031 in healthy volunteers. Muscle and Nerve, 2013, 47, 416-423.	1.0	138
129	Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E171-E182.	1.8	38
130	Depletion of stromal cells expressing fibroblast activation protein-Î± from skeletal muscle and bone marrow results in cachexia and anemia. Journal of Experimental Medicine, 2013, 210, 1137-1151.	4.2	304
131	Chronic Î±-hydroxyisocaproic acid treatment improves muscle recovery after immobilization-induced atrophy. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E416-E428.	1.8	23
132	TNF-<i>Î±</i>and IFN-s-Dependent Muscle Decay Is Linked to NF-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi mathvariant="bold-italic">Îº</mml:mi></mml:mrow></mml:math>B- and STAT-1<i>Î±</i>-Stimulated<i>Atrogin1</i>and<i>MuRF1</i>Genes in C2C12 Myotubes. Mediators of Inflammation, 2013, 2013, 1-18.	1.4	24
133	The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. Journal of Cell Biology, 2013, 203, 345-357.	2.3	166
134	Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Current Opinion in Supportive and Palliative Care, 2013, 7, 352-360.	0.5	127
135	The methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the <i>myostatin</i> and <i>c-Met</i> genes and regulates skeletal muscle atrophy. Genes and Development, 2013, 27, 1299-1312.	2.7	74
136	Isolation, characterization, and molecular regulation of muscle stem cells. Frontiers in Physiology, 2013, 4, 317.	1.3	35
137	Insulin Resistance and Muscle Metabolism in Chronic Kidney Disease. Isrn Endocrinology, 2013, 2013, 1-14.	2.0	17

#	Article	IF	Citations
138	Cancer, cachexia, prostanoids, and NSAIDs. Acta OncolÃ³gica, 2013, 52, 3-5.	0.8	4
139	Early changes of muscle insulinâ€like growth factorâ€1 and myostatin gene expression in gastric cancer patients. Muscle and Nerve, 2013, 48, 387-392.	1.0	26
140	TSC22D4 is a molecular output of hepatic wasting metabolism. EMBO Molecular Medicine, 2013, 5, 294-308.	3.3	57
141	Generation of a conditional mouse model to target <i>Acvr1b</i> disruption in adult tissues. Genesis, 2013, 51, 120-127.	0.8	12
142	Diaphragm and ventilatory dysfunction during cancer cachexia. FASEB Journal, 2013, 27, 2600-2610.	0.2	90
143	Cellular and molecular mechanisms of muscle atrophy. DMM Disease Models and Mechanisms, 2013, 6, 25-39.	1.2	958
144	Increasing muscle mass to improve metabolism. Adipocyte, 2013, 2, 92-98.	1.3	30
145	Myostatin induces mitochondrial metabolic alteration and typical apoptosis in cancer cells. Cell Death and Disease, 2013, 4, e494-e494.	2.7	29
146	Serum activin A and B levels predict outcome in patients with acute respiratory failure: a prospective cohort study. Critical Care, 2013, 17, R263.	2.5	33
147	State of the art paper Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. Archives of Medical Science, 2013, 1, 166-171.	0.4	25
148	Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. Drug Design, Development and Therapy, 2013, 7, 645.	2.0	14
149	Pancreatic cancer cachexia: a review of mechanisms and therapeutics. Frontiers in Physiology, 2014, 5, 88.	1.3	94
150	Potential Roles of mTOR and Protein Degradation Pathways in the Phenotypic Expression of Feed Efficiency in Broilers. Biochemistry & Physiology, 2014, 03, .	0.2	4
152	Ghrelin relieves cancer cachexia associated with the development of lung adenocarcinoma in mice. European Journal of Pharmacology, 2014, 743, 1-10.	1.7	34
153	The role of vitamin D in skeletal and cardiac muscle function. Frontiers in Physiology, 2014, 5, 145.	1.3	47
154	Denervation atrophy is independent from Akt and mTOR activation and is not rescued by myostatin inhibition. DMM Disease Models and Mechanisms, 2014, 7, 471-81.	1.2	55
155	Muscle wasting: an overview of recent developments in basic research. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 193-198.	2.9	37
156	Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. European Heart Journal, 2014, 35, 932-941.	1.0	167

#	Article	IF	Citations
157	An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy. Molecular and Cellular Biology, 2014, 34, 606-618.	1.1	239
158	Myostatin Regulates Tissue Potency and Cardiac Calcium-Handling Proteins. Endocrinology, 2014, 155, 1771-1785.	1.4	15
159	Endotoxemia-induced muscle wasting is associated with the change of hypothalamic neuropeptides in rats. Neuropeptides, 2014, 48, 379-386.	0.9	10
160	Opportunities for Targeting the Fatigue-Anorexia-Cachexia Symptom Cluster. Cancer Journal (Sudbury,) Tj ETQq1 1 0.784314 rgBT /O	1.0	13
161	Regenerating Skeletal Muscle in the Face of Aging and Disease. American Journal of Physical Medicine and Rehabilitation, 2014, 93, S88-S96.	0.7	17
162	Cardiac Atrophy and Remodeling. , 2014, , 37-50.		7
163	Loss of Mitochondria during Skeletal Muscle Atrophy. , 2014, , 239-251.		0
164	Inflammation Based Regulation of Cancer Cachexia. BioMed Research International, 2014, 2014, 1-7.	0.9	121
165	Cancer cachexia: towards integrated therapeutic interventions. Expert Opinion on Biological Therapy, 2014, 14, 1379-1381.	1.4	7
166	Gastric cancer does not affect the expression of atrophy-related genes in human skeletal muscle. Muscle and Nerve, 2014, 49, 528-533.	1.0	28
167	Mechanisms of cisplatin-induced muscle atrophy. Toxicology and Applied Pharmacology, 2014, 278, 190-199.	1.3	74
168	Pharmacological Strategies in Lung Cancer-Induced Cachexia: Effects on Muscle Proteolysis, Autophagy, Structure, and Weakness. Journal of Cellular Physiology, 2014, 229, 1660-1672.	2.0	77
169	Isotopic decay of urinary or plasma 3â€methylhistidine as a potential biomarker of pathologic skeletal muscle loss. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 19-25.	2.9	40
170	The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 149-158.	2.9	58
171	Mechanisms of muscle growth and atrophy in mammals and <i>Drosophila</i>. Developmental Dynamics, 2014, 243, 201-215.	0.8	112
172	Elevated expression of activins promotes muscle wasting and cachexia. FASEB Journal, 2014, 28, 1711-1723.	0.2	163
173	Myostatin Gene Inactivation Prevents Skeletal Muscle Wasting in Cancer. Cancer Research, 2014, 74, 7344-7356.	0.4	86
174	Phase II drugs that are currently in development for the treatment of cachexia. Expert Opinion on Investigational Drugs, 2014, 23, 1655-1669.	1.9	35

#	Article	IF	Citations
175	Molecular Mechanisms of Bone Metastasis and Associated Muscle Weakness. Clinical Cancer Research, 2014, 20, 3071-3077.	3.2	91
176	TGFÎ² and BMP signaling in skeletal muscle: potential significance for muscle-related disease. Trends in Endocrinology and Metabolism, 2014, 25, 464-471.	3.1	144
177	Myostatin is a key mediator between energy metabolism and endurance capacity of skeletal muscle. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2014, 307, R444-R454.	0.9	65
178	Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways. Cellular and Molecular Life Sciences, 2014, 71, 4361-4371.	2.4	297
179	A Switch from White to Brown Fat Increases Energy Expenditure in Cancer-Associated Cachexia. Cell Metabolism, 2014, 20, 433-447.	7.2	535
180	MicroRNAs differentially regulated in cardiac and skeletal muscle in health and disease: Potential drug targets?. Clinical and Experimental Pharmacology and Physiology, 2014, 41, n/a-n/a.	0.9	24
181	Muscle wasting: An overview of recent developments in basic research. International Journal of Cardiology, 2014, 176, 640-644.	0.8	26
182	Follistatin: A Novel Therapeutic for the Improvement of Muscle Regeneration. Journal of Pharmacology and Experimental Therapeutics, 2014, 349, 355-371.	1.3	55
183	Inhibition of Activin A Ameliorates Skeletal Muscle Injury and Rescues Contractile Properties by Inducing Efficient Remodeling in Female Mice. American Journal of Pathology, 2014, 184, 1152-1166.	1.9	28
184	Therapies for Musculoskeletal Disease: Can we Treat Two Birds with One Stone?. Current Osteoporosis Reports, 2014, 12, 142-153.	1.5	79
185	Amelioration of Colorectal Cancer Using Negative Lipidoid Nanoparticles to Encapsulate siRNA Against APRIL by Enema Delivery Mode. Pathology and Oncology Research, 2014, 20, 953-964.	0.9	7
186	Concurrent evolution of cancer cachexia and heart failure: bilateral effects exist. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 95-104.	2.9	62
187	Modeling human cancer cachexia in colon 26 tumorâ€bearing adult mice. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 321-328.	2.9	64
188	Myostatin â€" From the Mighty Mouse to cardiovascular disease and cachexia. Clinica Chimica Acta, 2014, 433, 216-224.	0.5	52
189	Mechanisms of muscle wasting in chronic kidney disease. Nature Reviews Nephrology, 2014, 10, 504-516.	4.1	444
190	Cancer cachexia: understanding the molecular basis. Nature Reviews Cancer, 2014, 14, 754-762.	12.8	991
191	Anorexiaâ€"cachexia syndrome in pancreatic cancer: Recent advances and new pharmacological approach. Advances in Medical Sciences, 2014, 59, 1-6.	0.9	35
192	Trim32 reduces PI3Kâ€"Aktâ€"FoxO signaling in muscle atrophy by promoting plakoglobinâ€"PI3K dissociation. Journal of Cell Biology, 2014, 204, 747-758.	2.3	82

#	Article	IF	Citations
193	Molecular targets of cancer cachexia: Opportunities for pharmanutritional approaches. PharmaNutrition, 2014, 2, 126-128.	0.8	4
194	Ghrelin prevents tumourâ€•and cisplatinâ€induced muscle wasting: characterization of multiple mechanisms involved. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 132-143.	2.9	165
195	Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 317-324.	2.9	137
196	Evaluation of follistatin as a therapeutic in models of skeletal muscle atrophy associated with denervation and tenotomy. Scientific Reports, 2015, 5, 17535.	1.6	29
198	Activin-A signaling promotes epithelialâ€"mesenchymal transition, invasion, and metastatic growth of breast cancer. Npj Breast Cancer, 2015, 1, 15007.	2.3	64
199	Administration of soluble activin receptor 2B increases bone and muscle mass in a mouse model of osteogenesis imperfecta. Bone Research, 2015, 3, 14042.	5.4	42
200	Systematic review of sarcopenia in patients operated on for gastrointestinal and hepatopancreatobiliary malignancies. British Journal of Surgery, 2015, 102, 1448-1458.	0.1	226
201	A shared mechanism of muscle wasting in cancer and Huntington's disease. Clinical and Translational Medicine, 2015, 4, 34.	1.7	22
202	Myostatin: Expanding horizons. IUBMB Life, 2015, 67, 589-600.	1.5	98
203	Sarcopenia impairs survival in patients with potentially curable hepatocellular carcinoma. Journal of Surgical Oncology, 2015, 112, 208-213.	0.8	80
204	Tumor inoculation site affects the development of cancer cachexia and muscle wasting. International Journal of Cancer, 2015, 137, 2558-2565.	2.3	34
205	Bone and morphogenetic protein signalling and muscle mass. Current Opinion in Clinical Nutrition and Metabolic Care, 2015, 18, 215-220.	1.3	19
206	Cachexia: The last illness. Nature, 2015, 528, 182-183.	13.7	55
207	The quasi-parallel lives of satellite cells and atrophying muscle. Frontiers in Aging Neuroscience, 2015, 7, 140.	1.7	5
208	Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. Journal of Cancer, 2015, 6, 310-318.	1.2	20
209	Satellite cells in human skeletal muscle plasticity. Frontiers in Physiology, 2015, 6, 283.	1.3	236
210	Cancer as a Proinflammatory Environment: Metastasis and Cachexia. Mediators of Inflammation, 2015, 2015, 1-13.	1.4	48
211	Nonmuscle Tissues Contribution to Cancer Cachexia. Mediators of Inflammation, 2015, 2015, 1-9.	1.4	43

#	Article	IF	Citations
212	Current and Future Care of Patients with the Cancer Anorexia-Cachexia Syndrome. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e229-e237.	1.8	27
213	Cancer-associated muscle weakness: What's bone got to do with it?. BoneKEy Reports, 2015, 4, 691.	2.7	33
214	MiR-181a: a potential biomarker of acute muscle wasting following elective high-risk cardiothoracic surgery. Critical Care, 2015, 19, 147.	2.5	18
215	Skeletal muscle atrophy: Potential therapeutic agents and their mechanisms of action. Pharmacological Research, 2015, 99, 86-100.	3.1	139
216	Cancer cachexia, mechanism and treatment. World Journal of Gastrointestinal Oncology, 2015, 7, 17.	0.8	323
217	Aerobic exercise training as therapy for cardiac and cancer cachexia. Life Sciences, 2015, 125, 9-14.	2.0	61
218	Role of Activin A and Myostatin in Human Cancer Cachexia. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2030-2038.	1.8	155
219	The regulation of muscle mass by endogenous glucocorticoids. Frontiers in Physiology, 2015, 6, 12.	1.3	169
220	Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 197-207.	2.9	300
221	Activin-Î² _Cmodulates cachexia by repressing the ubiquitin-proteasome and autophagic degradation pathways. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 365-380.	2.9	27
222	Cardiac and skeletal muscles show molecularly distinct responses to cancer cachexia. Physiological Genomics, 2015, 47, 588-599.	1.0	33
223	Mechanisms of Cachexia in Chronic Disease States. American Journal of the Medical Sciences, 2015, 350, 250-256.	0.4	85
224	The effects of whey protein with or without carbohydrates on resistance training adaptations. Journal of the International Society of Sports Nutrition, 2015, 12, 48.	1.7	39
225	Cardiac cachexia: hic et nunc. International Journal of Cardiology, 2015, 201, e1-e12.	0.8	18
226	The complex liaison between cachexia and tumor burden (Review). Oncology Reports, 2015, 34, 1635-1649.	1.2	14
227	Muscle wasting in disease: molecular mechanisms and promising therapies. Nature Reviews Drug Discovery, 2015, 14, 58-74.	21.5	792
228	Skeletal muscle anabolism in patients with advanced cancer. Lancet Oncology, The, 2015, 16, 13-14.	5.1	36
229	Diagnostic histochemistry and clinical-pathological testings as molecular pathways to pathogenesis and treatment of the ageing neuromuscular system: a personal view. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 563-584.	1.8	8

#	Article	IF	Citations
230	Integrated Therapies for Osteoporosis and Sarcopenia: From Signaling Pathways to Clinical Trials. Calcified Tissue International, 2015, 96, 243-255.	1.5	32
231	Adipose tissue lipolysis and energy metabolism in early cancer cachexia in mice. Cancer Biology and Therapy, 2015, 16, 886-897.	1.5	65
232	Identification of the Minimum Peptide from Mouse Myostatin Prodomain for Human Myostatin Inhibition. Journal of Medicinal Chemistry, 2015, 58, 1544-1549.	2.9	40
233	External physical and biochemical stimulation to enhance skeletal muscle bioengineering. Advanced Drug Delivery Reviews, 2015, 82-83, 168-175.	6.6	33
234	Nutritional Risk Index predicts mortality in hospitalized advanced heart failure patients. Journal of Heart and Lung Transplantation, 2015, 34, 1385-1389.	0.3	68
235	Virtual High-Throughput Screening To Identify Novel Activin Antagonists. Journal of Medicinal Chemistry, 2015, 58, 5637-5648.	2.9	17
236	Differential control of muscle mass in type 1 and type 2 diabetes mellitus. Cellular and Molecular Life Sciences, 2015, 72, 3803-3817.	2.4	32
237	BMPs and the muscleâ€"bone connection. Bone, 2015, 80, 37-42.	1.4	34
238	Cancer cachexia update in head and neck cancer: Definitions and diagnostic features. Head and Neck, 2015, 37, 594-604.	0.9	59
239	Inhibition of Stat3 Activation Suppresses Caspase-3 and the Ubiquitin-Proteasome System, Leading to Preservation of Muscle Mass in Cancer Cachexia. Journal of Biological Chemistry, 2015, 290, 11177-11187.	1.6	164
240	Loss of BMPR2 leads to high bone mass due to increased osteoblast activity. Journal of Cell Science, 2015, 128, 1308-1315.	1.2	50
241	Developing models for cachexia and their implications in drug discovery. Expert Opinion on Drug Discovery, 2015, 10, 743-752.	2.5	15
242	Cancer Cachexia, Recent Advances, and Future Directions. Cancer Journal (Sudbury, Mass), 2015, 21, 117-122.	1.0	62
243	Reduced Circulating GDF11 Is Unlikely Responsible for Age-Dependent Changes in Mouse Heart, Muscle, and Brain. Endocrinology, 2015, 156, 3885-3888.	1.4	87
244	Pilot study of a myostatin antagonist in dogs with cardiac cachexia. Journal of Veterinary Cardiology, 2015, 17, 210-215.	0.3	5
245	Emerging therapeutic concepts for muscle and bone preservation/formation. Bone, 2015, 80, 157-161.	1.4	2
246	Re-evaluating the role of activin-Î²C in cancer biology. Cytokine and Growth Factor Reviews, 2015, 26, 463-470.	3.2	3
247	Integrated analysis of serum and intact muscle metabonomics identify metabolic profiles of cancer cachexia in a dynamic mouse model. RSC Advances, 2015, 5, 92438-92448.	1.7	10

#	Article	IF	Citations
248	The role of mTOR signaling in the regulation of protein synthesis and muscle mass during immobilization in mice. DMM Disease Models and Mechanisms, 2015, 8, 1059-1069.	1.2	108
249	Excess TGF-Î² mediates muscle weakness associated with bone metastases in mice. Nature Medicine, 2015, 21, 1262-1271.	15.2	300
250	Cancer Cachexia: Emerging pre-clinical evidence and the pathway forward to clinical trials. Journal of the National Cancer Institute, 2015, 107, djv322.	3.0	3
251	Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival. Cell, 2015, 162, 1365-1378.	13.5	121
252	Letter by McLean and Oudit Regarding Article, â€œMyostatin Regulates Energy Homeostasis in the Heart and Prevents Heart Failureâ€. Circulation Research, 2015, 116, e51-2.	2.0	2
253	Molecular and neuroendocrine mechanisms of cancer cachexia. Journal of Endocrinology, 2015, 226, R29-R43.	1.2	66
254	A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia. Journal of Biological Chemistry, 2015, 290, 19976-19986.	1.6	92
255	Pharmacology of manipulating lean body mass. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 1-13.	0.9	12
256	Uncovering methods for the prevention of protein aggregation and improvement of product quality in a transient expression system. Biotechnology Progress, 2015, 31, 258-267.	1.3	27
257	Muscle-specific GSK-3Î² ablation accelerates regeneration of disuse-atrophied skeletal muscle. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 490-506.	1.8	47
258	The effects of an ActRIIb receptor Fc fusion protein ligand trap in juvenile simian immunodeficiency virusâ€infected rhesus macaques. FASEB Journal, 2015, 29, 1165-1175.	0.2	14
259	Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Letters, 2015, 356, 819-827.	3.2	75
260	Development of Novel Activin-Targeted Therapeutics. Molecular Therapy, 2015, 23, 434-444.	3.7	46
261	Myostatin/activin blocking combined with exercise reconditions skeletal muscle expression profile of mdx mice. Molecular and Cellular Endocrinology, 2015, 399, 131-142.	1.6	21
262	Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget, 2016, 7, 43442-43460.	0.8	145
263	Muscle Protein Kinetics in Cancer Cachexia. , 2016, , 133-144.		1
264	Notch Signaling Mediates Skeletal Muscle Atrophy in Cancer Cachexia Caused by Osteosarcoma. Sarcoma, 2016, 2016, 1-12.	0.7	33
265	Integrated expression analysis of muscle hypertrophy identifies Asb2 as a negative regulator of muscle mass. JCI Insight, 2016, 1, .	2.3	38

#	Article	IF	Citations
266	Disease-Induced Skeletal Muscle Atrophy and Fatigue. Medicine and Science in Sports and Exercise, 2016, 48, 2307-2319.	0.2	128
267	Novel therapeutic options for cachexia and sarcopenia. Expert Opinion on Biological Therapy, 2016, 16, 1239-1244.	1.4	44
268	ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skeletal Muscle, 2016, 6, 26.	1.9	70
269	Comparative molecular analysis of early and late cancer cachexia-induced muscle wasting in mouse models. Oncology Reports, 2016, 36, 3291-3302.	1.2	15
270	Two Activin Type 2B Receptors from Sea Bream Function Similarly <i>in vitro</i>. Biological Bulletin, 2016, 230, 56-67.	0.7	0
271	Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPÎ²-regulated atrogin1 expression in cancer cachexia. American Journal of Physiology - Cell Physiology, 2016, 311, C101-C115.	2.1	35
272	Hypothalamic activation is essential for endotoxemia-induced acute muscle wasting. Scientific Reports, 2016, 6, 38544.	1.6	9
273	Leucine-rich diet alters the 1H-NMR based metabolomic profile without changing the Walker-256 tumour mass in rats. BMC Cancer, 2016, 16, 764.	1.1	28
274	A non-human primate model of radiation-induced cachexia. Scientific Reports, 2016, 6, 23612.	1.6	22
275	Activins and their related proteins in colon carcinogenesis: insights from early and advanced azoxymethane rat models of colon cancer. BMC Cancer, 2016, 16, 879.	1.1	8
276	Ovarian cancer: avoiding compromising quality of life during intense chemotherapy sessions. Expert Review of Quality of Life in Cancer Care, 2016, 1, 277-288.	0.6	0
277	Growth Factors and Cytokines in Skeletal Muscle Development, Growth, Regeneration and Disease. Advances in Experimental Medicine and Biology, 2016, , .	0.8	3
278	Inhibition of Activin Signaling Slows Progression of Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 3589-3599.	3.0	42
279	Ataxin-10 is part of a cachexokine cocktail triggering cardiac metabolic dysfunction in cancer cachexia. Molecular Metabolism, 2016, 5, 67-78.	3.0	51
280	Delphinidin prevents disuse muscle atrophy and reduces stress-related gene expression. Bioscience, Biotechnology and Biochemistry, 2016, 80, 1636-1640.	0.6	14
281	Mechanisms of metabolic dysfunction in cancer-associated cachexia. Genes and Development, 2016, 30, 489-501.	2.7	239
282	TGF-Î² and the TGF-Î² Family: Context-Dependent Roles in Cell and Tissue Physiology. Cold Spring Harbor Perspectives in Biology, 2016, 8, a021873.	2.3	876
283	Pay attention to cardiac remodeling in cancer cachexia. Supportive Care in Cancer, 2016, 24, 3253-9.	1.0	11

#	Article	IF	Citations
284	TGFÎ² Superfamily Members Mediate Androgen Deprivation Therapy-Induced Obese Frailty in Male Mice. Endocrinology, 2016, 157, 4461-4472.	1.4	18
285	Establishment and phenotypic analysis of an Mstn knockout rat. Biochemical and Biophysical Research Communications, 2016, 477, 115-122.	1.0	35
286	Silencing Myostatin Using Cholesterol-conjugated siRNAs Induces Muscle Growth. Molecular Therapy - Nucleic Acids, 2016, 5, e342.	2.3	62
287	Cardiac cachexia: hic et nunc. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 246-260.	2.9	103
288	Cancer cachexiaâ€"when proteasomal inhibition is not enough. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 239-245.	2.9	14
289	Regulation of Hspb7 by MEF2 and AP-1: implications for Hspb7 in muscle atrophy. Journal of Cell Science, 2016, 129, 4076-4090.	1.2	15
290	Activin Decoy Receptor ActRIIB:Fc Lowers FSH and Therapeutically Restores Oocyte Yield, Prevents Oocyte Chromosome Misalignments and Spindle Aberrations, and Increases Fertility in Midlife Female SAMP8 Mice. Endocrinology, 2016, 157, 1234-1247.	1.4	5
291	<i>Smad7</i> gene delivery prevents muscle wasting associated with cancer cachexia in mice. Science Translational Medicine, 2016, 8, 348ra98.	5.8	70
292	Dysregulation of RUNX2/Activin-A Axis upon miR-376c Downregulation Promotes Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma. Cancer Research, 2016, 76, 7140-7150.	0.4	47
293	Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes. Scientific Reports, 2016, 6, 32695.	1.6	55
294	Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. Cell Metabolism, 2016, 24, 672-684.	7.2	264
295	Effect of Nâ€Terminal Acylation on the Activity of Myostatin Inhibitory Peptides. ChemMedChem, 2016, 11, 845-849.	1.6	18
296	Future options of anti-angiogenic cancer therapy. Chinese Journal of Cancer, 2016, 35, 21.	4.9	42
297	Skeletal muscle wasting and renewal: a pivotal role of myokine IL-6. SpringerPlus, 2016, 5, 619.	1.2	141
298	Activins and Inhibins: Roles in Development, Physiology, and Disease. Cold Spring Harbor Perspectives in Biology, 2016, 8, a021881.	2.3	175
299	Animal models of cardiac cachexia. International Journal of Cardiology, 2016, 219, 105-110.	0.8	27
300	Molecular Pathways: Cachexia Signalingâ€"A Targeted Approach to Cancer Treatment. Clinical Cancer Research, 2016, 22, 3999-4004.	3.2	85
301	Differential Effects of IL6 and Activin A in the Development of Cancer-Associated Cachexia. Cancer Research, 2016, 76, 5372-5382.	0.4	62

#	Article	IF	Citations
302	Erythropoietin improves cardiac wasting and outcomes in a rat model of liver cancer cachexia. International Journal of Cardiology, 2016, 218, 312-317.	0.8	8
303	Pancreatic cancer cell-derived IGFBP-3 contributes to muscle wasting. Journal of Experimental and Clinical Cancer Research, 2016, 35, 46.	3.5	44
304	Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type <scp>II</scp> receptor inhibition and Î²â€2 agonist. International Journal of Cancer, 2016, 138, 2021-2029.	2.3	55
305	Omics/systems biology and cancer cachexia. Seminars in Cell and Developmental Biology, 2016, 54, 92-103.	2.3	26
306	Protein breakdown in cancer cachexia. Seminars in Cell and Developmental Biology, 2016, 54, 11-19.	2.3	114
307	Cachexia in patients with oesophageal cancer. Nature Reviews Clinical Oncology, 2016, 13, 185-198.	12.5	197
308	Systemic Nutrient and Stress Signaling via Myokines and Myometabolites. Annual Review of Physiology, 2016, 78, 85-107.	5.6	77
309	Caloric restriction and exercise â€œmimeticsâ€™â€™: Ready for prime time?. Pharmacological Research, 2016, 103, 158-166.	3.1	68
310	Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia â€" can findings from animal models be translated to humans?. BMC Cancer, 2016, 16, 75.	1.1	70
311	Transforming Growth Factor-Î² Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding. Journal of Biological Chemistry, 2016, 291, 10792-10804.	1.6	96
312	Cytokine Signaling in Skeletal Muscle Wasting. Trends in Endocrinology and Metabolism, 2016, 27, 335-347.	3.1	135
313	MAP3K11/GDF15 axis is a critical driver of cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 467-482.	2.9	125
314	The TGF-Î² Signalling Network in Muscle Development, Adaptation and Disease. Advances in Experimental Medicine and Biology, 2016, 900, 97-131.	0.8	56
315	BMP signalling in skeletal development, disease and repair. Nature Reviews Endocrinology, 2016, 12, 203-221.	4.3	607
316	The pathogenesis and treatment of cardiac atrophy in cancer cachexia. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H466-H477.	1.5	86
317	The emerging role of skeletal muscle oxidative metabolism as a biological target and cellular regulator of cancer-induced muscle wasting. Seminars in Cell and Developmental Biology, 2016, 54, 53-67.	2.3	82
318	Aerobic and resistance training dependent skeletal muscle plasticity in the colon-26 murine model of cancer cachexia. Metabolism: Clinical and Experimental, 2016, 65, 685-698.	1.5	67
319	STAT3 in the systemic inflammation of cancer cachexia. Seminars in Cell and Developmental Biology, 2016, 54, 28-41.	2.3	171

#	Article	IF	Citations
320	Understanding cachexia as a cancer metabolism syndrome. Oncogenesis, 2016, 5, e200-e200.	2.1	384
321	Antioxidant supplementation accelerates cachexia development by promoting tumor growth in C26 tumor-bearing mice. Free Radical Biology and Medicine, 2016, 91, 204-214.	1.3	46
322	ActivinB Is Induced in Insulinoma To Promote Tumor Plasticity through a Î²-Cell-Induced Dedifferentiation. Molecular and Cellular Biology, 2016, 36, 756-764.	1.1	13
323	Impaired regeneration: A role for the muscle microenvironment in cancer cachexia. Seminars in Cell and Developmental Biology, 2016, 54, 82-91.	2.3	52
324	Muscle-bone interactions: From experimental models to the clinic? A critical update. Molecular and Cellular Endocrinology, 2016, 432, 14-36.	1.6	115
325	Inhibition of myostatin in mice improves insulin sensitivity via irisin-mediated cross talk between muscle and adipose tissues. International Journal of Obesity, 2016, 40, 434-442.	1.6	155
326	Reversal of muscle atrophy by Zhimu and Huangbai herb pair via activation of IGF-1/Akt and autophagy signal in cancer cachexia. Supportive Care in Cancer, 2016, 24, 1189-1198.	1.0	26
327	Gonadal Peptides. , 2016, , 2037-2050.e6.		1
328	Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut, 2016, 65, 1165-1174.	6.1	173
329	The 2015 ESPEN Sir David Cuthbertson lecture: Inflammation as the driving force of muscle wasting in cancer. Clinical Nutrition, 2017, 36, 798-803.	2.3	22
330	Molecular mechanism of sarcopenia and cachexia: recent research advances. Pflugers Archiv European Journal of Physiology, 2017, 469, 573-591.	1.3	114
331	Increased thrombin generation in a mouse model of cancer cachexia is partially interleukinâ€6 dependent. Journal of Thrombosis and Haemostasis, 2017, 15, 477-486.	1.9	28
332	Administration of an activin receptor IIB ligand trap protects male juvenile rhesus macaques from simian immunodeficiency virus-associated bone loss. Bone, 2017, 97, 209-215.	1.4	6
333	Supraphysiological levels of <scp>GDF</scp> 11 induce striated muscle atrophy. EMBO Molecular Medicine, 2017, 9, 531-544.	3.3	99
334	Role of PARP activity in lung cancerâ€induced cachexia: Effects on muscle oxidative stress, proteolysis, anabolic markers, and phenotype. Journal of Cellular Physiology, 2017, 232, 3744-3761.	2.0	44
335	Drosophila melanogaster as a Model of Muscle Degeneration Disorders. Current Topics in Developmental Biology, 2017, 121, 83-109.	1.0	33
336	Loop diuretics affect skeletal myoblast differentiation and exercise-induced muscle hypertrophy. Scientific Reports, 2017, 7, 46369.	1.6	39
337	Bone Pain and Muscle Weakness in Cancer Patients. Current Osteoporosis Reports, 2017, 15, 76-87.	1.5	23

#	Article	IF	Citations
338	Molecular effects of exercise training in patients with cardiovascular disease: focus on skeletal muscle, endothelium, and myocardium. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H72-H88.	1.5	96
339	Cancer-induced muscle wasting: latest findings in prevention and treatment. Therapeutic Advances in Medical Oncology, 2017, 9, 369-382.	1.4	154
340	Activin A induces skeletal muscle catabolism via p38Î² mitogenâ€activated protein kinase. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 202-212.	2.9	62
341	Structural Basis for the Effective Myostatin Inhibition of the Mouse Myostatin Prodomain-Derived Minimum Peptide. ACS Medicinal Chemistry Letters, 2017, 8, 113-117.	1.3	17
342	Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling. Scientific Reports, 2017, 7, 2046.	1.6	85
343	Metabolic Inflammatory Complex in Sepsis: Septic Cachexia as a Novel Potential Therapeutic Target. Shock, 2017, 48, 600-609.	1.0	18
344	Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice. European Journal of Pharmacology, 2017, 811, 30-37.	1.7	17
345	Development of Potent Myostatin Inhibitory Peptides through Hydrophobic Residue-Directed Structural Modification. ACS Medicinal Chemistry Letters, 2017, 8, 751-756.	1.3	20
346	Specific targeting of TGF-Î² family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E5266-E5275.	3.3	90
347	Reduced skeletal muscle fiber size following caloric restriction is associated with calpain-mediated proteolysis and attenuation of IGF-1 signaling. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2017, 312, R806-R815.	0.9	24
348	Connecting the Metabolic and Immune Responses to Cancer. Trends in Molecular Medicine, 2017, 23, 451-464.	3.5	55
349	Animal models of cachexia and sarcopenia in chronic illness: Cardiac function, body composition changes and therapeutic results. International Journal of Cardiology, 2017, 238, 12-18.	0.8	22
350	The Association of Computed Tomography-Assessed Body Composition with Mortality in Patients with Necrotizing Pancreatitis. Journal of Gastrointestinal Surgery, 2017, 21, 1000-1008.	0.9	20
351	Panoramic ultrasound: a novel and valid tool for monitoring change in muscle mass. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 475-481.	2.9	60
352	Pharmacological inhibition of myostatin improves skeletal muscle mass and function in a mouse model of stroke. Scientific Reports, 2017, 7, 14000.	1.6	31
353	Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer. Molecular Cancer Therapeutics, 2017, 16, 2747-2758.	1.9	19
354	Skeletal muscle alterations in HFrEF vs. HFpEF. Current Heart Failure Reports, 2017, 14, 489-497.	1.3	39
355	Paracrine Activin-A Signaling Promotes Melanoma Growth and Metastasis through Immune Evasion. Journal of Investigative Dermatology, 2017, 137, 2578-2587.	0.3	27

#	Article	IF	Citations
356	Activin A more prominently regulates muscle mass in primates than does GDF8. Nature Communications, 2017, 8, 15153.	5.8	129
357	The role of omega-3 fatty acids in skeletal muscle anabolism, strength, and function in healthy and diseased states. Journal of Food Biochemistry, 2017, 41, e12435.	1.2	3
358	Biomarkers of cancer cachexia. Clinical Biochemistry, 2017, 50, 1281-1288.	0.8	86
359	Circulating <scp>Activin A</scp> predicts survival in cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 768-777.	2.9	61
360	Activin signaling is an essential component of the TGF-Î² induced pro-metastatic phenotype in colorectal cancer. Scientific Reports, 2017, 7, 5569.	1.6	55
361	Comparative Proteomic and Transcriptomic Analysis of Follistatin-Induced Skeletal Muscle Hypertrophy. Journal of Proteome Research, 2017, 16, 3477-3490.	1.8	22
362	Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival. Nature Communications, 2017, 8, 1707.	5.8	86
363	Cardiac muscle wasting in individuals with cancer cachexia. ESC Heart Failure, 2017, 4, 458-467.	1.4	80
364	Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12448-12453.	3.3	93
365	ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Scientific Reports, 2017, 7, 14470.	1.6	44
366	Bone mineral density and content are differentially impacted by aerobic and resistance training in the colon-26 mouse model of cancer cachexia. Applied Cancer Research, 2017, 37, .	1.0	1
367	Transforming Growth Factor Î² Superfamily Signaling inÂDevelopment of Colorectal Cancer. Gastroenterology, 2017, 152, 36-52.	0.6	181
368	New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 122-130.	2.9	55
369	Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation. Molecular Cancer Therapeutics, 2017, 16, 334-343.	1.9	48
370	Ammonia elicits a different myogenic response in avian and murine myotubes. In Vitro Cellular and Developmental Biology - Animal, 2017, 53, 99-110.	0.7	9
371	Metabolic Changes During Cancer Cachexia Pathogenesis. Advances in Experimental Medicine and Biology, 2017, 1026, 233-249.	0.8	32
372	Cancer-induced cardiac cachexia: Pathogenesis and impact of physical activity. Oncology Reports, 2017, 37, 2543-2552.	1.2	55
373	1. Physiologische und molekularbiologische Mechanismen. , 2017, , .		0

#	Article	IF	Citations
374	Pyrrolidine Dithiocarbamate (PDTC) Attenuates Cancer Cachexia by Affecting Muscle Atrophy and Fat Lipolysis. Frontiers in Pharmacology, 2017, 8, 915.	1.6	26
375	Differential Bone Loss in Mouse Models of Colon Cancer Cachexia. Frontiers in Physiology, 2016, 7, 679.	1.3	44
376	The MEK-Inhibitor Selumetinib Attenuates Tumor Growth and Reduces IL-6 Expression but Does Not Protect against Muscle Wasting in Lewis Lung Cancer Cachexia. Frontiers in Physiology, 2016, 7, 682.	1.3	20
377	The Effect of Resistance Exercise on Inflammatory and Myogenic Markers in Patients with Chronic Kidney Disease. Frontiers in Physiology, 2017, 8, 541.	1.3	32
378	Chinese Herbal Medicine Baoyuan Jiedu Decoction Inhibited Muscle Atrophy of Cancer Cachexia through Atrogin-l and MuRF-1. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-10.	0.5	7
379	Dexmedetomidine ameliorates muscle wasting and attenuates the alteration of hypothalamic neuropeptides and inflammation in endotoxemic rats. PLoS ONE, 2017, 12, e0174894.	1.1	9
380	Ligand-induced rapid skeletal muscle atrophy in HSA-Fv2E-PERK transgenic mice. PLoS ONE, 2017, 12, e0179955.	1.1	10
381	Nutritional Management of Esophageal Cancer Patients. , 0, , .		4
382	Cancer-associated cachexia. Nature Reviews Disease Primers, 2018, 4, 17105.	18.1	908
383	Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer. Clinical Radiology, 2018, 73, 505.e1-505.e8.	0.5	13
384	Fenofibrate prevents skeletal muscle loss in mice with lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E743-E752.	3.3	89
385	Preclinical and clinical studies on cancer-associated cachexia. Frontiers in Biology, 2018, 13, 11-18.	0.7	1
386	Myostatin: Twenty Years Later. Human Physiology, 2018, 44, 88-101.	0.1	7
387	Bone Morphogenetic Proteinâ€"Based Therapeutic Approaches. Cold Spring Harbor Perspectives in Biology, 2018, 10, a022327.	2.3	53
388	Soluble activin receptor type IIB decoy receptor differentially impacts murine osteogenesis imperfecta muscle function. Muscle and Nerve, 2018, 57, 294-304.	1.0	20
389	Contrast-enhancement influences skeletal muscle density, but not skeletal muscle mass, measurements on computed tomography. Clinical Nutrition, 2018, 37, 1707-1714.	2.3	89
390	Systemic SMAD7 Gene Therapy Increases Striated Muscle Mass and Enhances Exercise Capacity in a Dose-Dependent Manner. Human Gene Therapy, 2018, 29, 390-399.	1.4	5
391	Low skeletal muscle mass is associated with increased hospital costs in patients with cirrhosis listed for liver transplantation-a retrospective study. Transplant International, 2018, 31, 165-174.	0.8	64

#	Article	IF	Citations
392	Prevention of chemotherapyâ€induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 417-432.	2.9	48
393	Serum and urine metabolomics study reveals a distinct diagnostic model for cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 71-85.	2.9	107
394	Muscle wasting and survival following pre-operative chemoradiotherapy for locally advanced rectal carcinoma. Clinical Nutrition, 2018, 37, 1728-1735.	2.3	33
395	Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival. JNCI Cancer Spectrum, 2018, 2, pky043.	1.4	54
396	Prognostic Significance of Sarcopenia With Inflammation in Patients With Head and Neck Cancer Who Underwent Definitive Chemoradiotherapy. Frontiers in Oncology, 2018, 8, 457.	1.3	81
397	Past, Present, and Future Perspective of Targeting Myostatin and Related Signaling Pathways to Counteract Muscle Atrophy. Advances in Experimental Medicine and Biology, 2018, 1088, 153-206.	0.8	27
398	Muscle Changes During Atrophy. Advances in Experimental Medicine and Biology, 2018, 1088, 73-92.	0.8	36
399	Emerging role of extracellular vesicles in mediating cancer cachexia. Biochemical Society Transactions, 2018, 46, 1129-1136.	1.6	46
400	Impact of Sarcopenia as a Prognostic Biomarker of Bladder Cancer. International Journal of Molecular Sciences, 2018, 19, 2999.	1.8	42
401	Cancer Cachexia: More Than Skeletal Muscle Wasting. Trends in Cancer, 2018, 4, 849-860.	3.8	123
403	Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA. Theranostics, 2018, 8, 5276-5288.	4.6	32
404	What's next in using CT scans to better understand cachexia?. Current Opinion in Supportive and Palliative Care, 2018, 12, 427-433.	0.5	4
405	Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin. JCI Insight, 2018, 3, .	2.3	57
406	Myostatin knockout induces apoptosis in human cervical cancer cells via elevated reactive oxygen species generation. Redox Biology, 2018, 19, 412-428.	3.9	24
407	A DGKÎ¶-FoxO-ubiquitin proteolytic axis controls fiber size during skeletal muscle remodeling. Science Signaling, 2018, 11, .	1.6	34
408	Obesity Paradox in Advanced Kidney Disease: From Bedside to the Bench. Progress in Cardiovascular Diseases, 2018, 61, 168-181.	1.6	73
409	Metabolic Alterations in a Slow-Paced Model of Pancreatic Cancer-Induced Wasting. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-10.	1.9	19
410	Knockout of USP19 Deubiquitinating Enzyme Prevents Muscle Wasting by Modulating Insulin and Glucocorticoid Signaling. Endocrinology, 2018, 159, 2966-2977.	1.4	11

#	Article	IF	Citations
411	Inhibition of the Activin Receptor Type-2B Pathway Restores Regenerative Capacity in Satellite Cell-Depleted Skeletal Muscle. Frontiers in Physiology, 2018, 9, 515.	1.3	11
412	LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 871-879.	2.9	80
413	Micro-computed tomography for non-invasive evaluation of muscle atrophy in mouse models of disease. PLoS ONE, 2018, 13, e0198089.	1.1	13
414	Centronuclear myopathies under attack: A plethora of therapeutic targets. Journal of Neuromuscular Diseases, 2018, 5, 387-406.	1.1	34
415	Platinum-induced muscle wasting in cancer chemotherapy: Mechanisms and potential targets for therapeutic intervention. Life Sciences, 2018, 208, 1-9.	2.0	42
416	Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 685-700.	2.9	74
417	Whey protein supplementation for the preservation of mass and muscular strength of patients with heart failure: study protocol for a randomized controlled trial. Trials, 2018, 19, 431.	0.7	4
418	Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 514-529.	2.9	53
419	Increased gut permeability in cancer cachexia: mechanisms and clinical relevance. Oncotarget, 2018, 9, 18224-18238.	0.8	90
420	The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexia. Journal of Applied Physiology, 2018, 125, 287-303.	1.2	24
421	Effects of an ActRIIB.Fc Ligand Trap on Cardiac Function in Simian Immunodeficiency Virus-Infected Male Rhesus Macaques. Journal of the Endocrine Society, 2018, 2, 817-831.	0.1	3
422	Pancreatic Cancerâ€"Induced Cachexia and Relevant Mouse Models. Pancreas, 2018, 47, 937-945.	0.5	43
423	Magnetic Resonance Imaging of Adipose Tissue in Metabolic Dysfunction. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2018, 190, 1121-1130.	0.7	11
424	The Muscle Stem Cell Niche in Health and Disease. Current Topics in Developmental Biology, 2018, 126, 23-65.	1.0	76
425	Twist1 Activation in Muscle Progenitor Cells Causes Muscle Loss Akin to Cancer Cachexia. Developmental Cell, 2018, 45, 712-725.e6.	3.1	38
426	Muscle Wasting Diseases: Novel Targets and Treatments. Annual Review of Pharmacology and Toxicology, 2019, 59, 315-339.	4.2	69
427	Hepatic Encephalopathy and Sarcopenia: Two Faces of the Same Metabolic Alteration. Journal of Clinical and Experimental Hepatology, 2019, 9, 125-130.	0.4	41
428	A Key Role for the Ubiquitin Ligase UBR4 in Myofiber Hypertrophy in Drosophila and Mice. Cell Reports, 2019, 28, 1268-1281.e6.	2.9	56

#	Article	IF	Citations
429	Molecular regulation of skeletal muscle mass and the contribution of nitric oxide: A review. FASEB BioAdvances, 2019, 1, 364-374.	1.3	23
430	A fully human transgene switch to regulate therapeutic protein production by cooling sensation. Nature Medicine, 2019, 25, 1266-1273.	15.2	38
431	The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 1083-1101.	2.9	46
432	Inhibition of activin-like kinase 4/5 attenuates cancer cachexia associated muscle wasting. Scientific Reports, 2019, 9, 9826.	1.6	13
433	Elevated serum Activin A in chronic obstructive pulmonary disease with skeletal muscle wasting. Clinics, 2019, 74, e981.	0.6	5
434	Ectopic TWEAKR expression in type I fiber of stroke-prone spontaneously hypertensive rats is related to slow muscle-specific hypotrophy. Life Sciences, 2019, 237, 116919.	2.0	1
435	TGF-Î² Signaling in Cellular Senescence and Aging-Related Pathology. International Journal of Molecular Sciences, 2019, 20, 5002.	1.8	185
436	Chemotherapyâ€induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. JCSM Rapid Communications, 2019, 2, 1-12.	0.6	34
437	Cachexia Anorexia Syndrome and Associated Metabolic Dysfunction in Peritoneal Metastasis. International Journal of Molecular Sciences, 2019, 20, 5444.	1.8	32
438	Evaluation of Parameters for Cancer-Induced Sarcopenia in Patients Autopsied after Death from Colorectal Cancer. Pathobiology, 2019, 86, 306-314.	1.9	10
439	Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients. Cancers, 2019, 11, 1619.	1.7	9
440	Giving combined mediumâ€chain fatty acids and glucose protects against cancerâ€associated skeletal muscle atrophy. Cancer Science, 2019, 110, 3391-3399.	1.7	14
441	Treatment with Soluble Activin Receptor Type IIB Alters Metabolic Response in Chemotherapy-Induced Cachexia. Cancers, 2019, 11, 1222.	1.7	12
443	Cancer Takes a Toll on Skeletal Muscle by Releasing Heat Shock Proteinsâ€"An Emerging Mechanism of Cancer-Induced Cachexia. Cancers, 2019, 11, 1272.	1.7	16
444	Activin Aâ€"Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice. Endocrinology, 2019, 160, 2417-2426.	1.4	17
445	Overcoming natureâ€™s paradox in skeletal muscle to optimise animal production. Animal Production Science, 2019, 59, 1957.	0.6	3
446	Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 2062-2069.	1.1	26
447	Skeletal Muscles Do Not Undergo Apoptosis During Either Atrophy or Programmed Cell Death-Revisiting the Myonuclear Domain Hypothesis. Frontiers in Physiology, 2018, 9, 1887.	1.3	52

#	Article	IF	Citations
448	Current pharmacotherapies for sarcopenia. Expert Opinion on Pharmacotherapy, 2019, 20, 1645-1657.	0.9	54
449	Activation of mTORC1 signalling in rat skeletal muscle is independent of the ECâ€coupling sequence but dependent on tension per se in a doseâ€response relationship. Acta Physiologica, 2019, 227, e13336.	1.8	18
450	Association between changes in subcutaneous fat mass and heart failure-induced cachexia: a case report. Journal of Physical Therapy Science, 2019, 31, 462-465.	0.2	0
451	Chain-Shortened Myostatin Inhibitory Peptides Improve Grip Strength in Mice. ACS Medicinal Chemistry Letters, 2019, 10, 985-990.	1.3	16
452	The clinical impact and biological mechanisms of skeletal muscle aging. Bone, 2019, 127, 26-36.	1.4	46
453	First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors. Clinical Cancer Research, 2019, 25, 5458-5465.	3.2	47
454	Tissue-specific dysregulation of mitochondrial respiratory capacity and coupling control in colon-26 tumor-induced cachexia. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2019, 317, R68-R82.	0.9	31
455	Opposing effects of 25â€hydroxyâ€and 1Î±,25â€dihydroxyâ€vitamin D₃ on proâ€cachectic cytokineâ€and cancer conditioned mediumâ€induced atrophy in C2C12 myotubes. Acta Physiologica, 2019, 226, e13269.	1.8	11
456	Activin type II receptor signaling in cardiac aging and heart failure. Science Translational Medicine, 2019, 11, .	5.8	95
457	Exercise-Induced Myokines With Therapeutic Potential for Muscle Wasting. Frontiers in Physiology, 2019, 10, 287.	1.3	90
458	Muscle and serum metabolomes are dysregulated in colon-26 tumor-bearing mice despite amelioration of cachexia with activin receptor type 2B ligand blockade. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E852-E865.	1.8	26
459	Inter- and Intracellular Mechanisms of Cardiac Remodeling, Hypertrophy and Dysfunction. Cardiovascular Medicine, 2019, , 39-56.	0.0	1
460	The Mechanical Stimulation of Myotubes Counteracts the Effects of Tumor-Derived Factors Through the Modulation of the Activin/Follistatin Ratio. Frontiers in Physiology, 2019, 10, 401.	1.3	23
461	IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway. Skeletal Muscle, 2019, 9, 8.	1.9	25
462	Staging of nutrition disorders in nonâ€smallâ€cell lung cancer patients: utility of skeletal muscle mass assessment. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 782-793.	2.9	17
463	Mediators of cachexia in cancer patients. Nutrition, 2019, 66, 11-15.	1.1	50
464	Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors. Journal of Geriatric Oncology, 2019, 10, 749-756.	0.5	13
465	Metabolic and Molecular Basis of Sarcopenia: Implications in the Management of Urothelial Carcinoma. International Journal of Molecular Sciences, 2019, 20, 760.	1.8	19

#	Article	IF	Citations
466	Systemic Blockade of ACVR2B Ligands Protects Myocardium from Acute Ischemia-Reperfusion Injury. Molecular Therapy, 2019, 27, 600-610.	3.7	25
467	Design and synthesis of potent myostatin inhibitory cyclic peptides. Bioorganic and Medicinal Chemistry, 2019, 27, 1437-1443.	1.4	10
468	Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy. Human Molecular Genetics, 2019, 28, 1076-1089.	1.4	76
470	Leptin induces muscle wasting in <i>kras</i>-driven hepatocellular carcinoma (HCC) model in zebrafish. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	21
471	Body Size and Tissue-Scaling Is Regulated by Motoneuron-Derived ActivinÃŸ in Drosophila melanogaster. Genetics, 2019, 213, 1447-1464.	1.2	25
472	Z-ajoene from Crushed Garlic Alleviates Cancer-Induced Skeletal Muscle Atrophy. Nutrients, 2019, 11, 2724.	1.7	17
473	Natural constituents from food sources: potential therapeutic agents against muscle wasting. Food and Function, 2019, 10, 6967-6986.	2.1	9
474	High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs. Medicine (United States), 2019, 98, e16875.	0.4	31
475	Cancer cachexia, a clinical challenge. Current Opinion in Oncology, 2019, 31, 286-290.	1.1	18
476	ER Stress and Unfolded Protein Response in Cancer Cachexia. Cancers, 2019, 11, 1929.	1.7	40
477	Exercise preserves muscle mass and force in a prostate cancer mouse model. European Journal of Translational Myology, 2019, 29, 8520.	0.8	10
478	Emerging role of myostatin and its inhibition in the setting of chronic kidney disease. Kidney International, 2019, 95, 506-517.	2.6	55
479	Alterations in serum amino-acid profile in the progression of colorectal cancer: associations with systemic inflammation, tumour stage and patient survival. British Journal of Cancer, 2019, 120, 238-246.	2.9	54
481	Cellular mechanisms promoting cachexia and how they are opposed by sirtuins. Canadian Journal of Physiology and Pharmacology, 2019, 97, 235-245.	0.7	2
482	Inter-tissue communication in cancer cachexia. Nature Reviews Endocrinology, 2019, 15, 9-20.	4.3	191
483	Activin Receptor Ligand Blocking and Cancer Have Distinct Effects on Protein and Redox Homeostasis in Skeletal Muscle and Liver. Frontiers in Physiology, 2019, 9, 1917.	1.3	8
484	Metabolic derangements of skeletal muscle from a murine model of glioma cachexia. Skeletal Muscle, 2019, 9, 3.	1.9	21
485	Increased hospital costs are associated with low skeletal muscle mass in patients undergoing elective open aortic surgery. Journal of Vascular Surgery, 2019, 69, 1227-1232.	0.6	8

#	Article	IF	Citations
486	Cancer cachexia impairs neural respiratory drive in hypoxia but not hypercapnia. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 63-72.	2.9	9
487	Activin A in Mammalian Physiology. Physiological Reviews, 2019, 99, 739-780.	13.1	117
488	Doubled lifespan and patientâ€like pathologies in progeria mice fed highâ€fat diet. Aging Cell, 2019, 18, e12852.	3.0	23
489	New insights on the regulation of cancer cachexia by N-3 polyunsaturated fatty acids. , 2019, 196, 117-134.		55
490	Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?. , 2019, 196, 135-159.		100
491	Cancer cachexia: getting to the heart of the matter. European Heart Journal, 2019, 40, e17-e19.	1.0	4
492	Low Skeletal Muscle Density Is Associated with Early Death in Patients with Perihilar Cholangiocarcinoma Regardless of Subsequent Treatment. Digestive Surgery, 2019, 36, 144-152.	0.6	31
493	Glucocorticoid Receptor Polymorphisms Influence Muscle Strength in Cushingâ€™s Syndrome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 305-313.	1.8	14
494	Autocrine activin A signalling in ovarian cancer cells regulates secretion of interleukin 6, autophagy, and cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 195-207.	2.9	31
495	Mechanisms underlying the crossâ€talk between heart and cancer. Journal of Physiology, 2020, 598, 3015-3027.	1.3	14
496	Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy. Clinical Lung Cancer, 2020, 21, e142-e150.	1.1	19
497	The Etiology and Impact of Muscle Wasting in Metastatic Cancer. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a037416.	2.9	8
498	Chronic Alcohol Consumption Enhances Skeletal Muscle Wasting in Mice Bearing Cachectic Cancers: The Role of TNFÎ±/Myostatin Axis. Alcoholism: Clinical and Experimental Research, 2020, 44, 66-77.	1.4	16
499	circRNAs and Exosomes: A Mysterious Frontier for Human Cancer. Molecular Therapy - Nucleic Acids, 2020, 19, 384-392.	2.3	98
500	Cancer Cachexia. , 2020, , 593-597.e1.		0
501	Exercise as an anti-inflammatory therapy for cancer cachexia: a focus on interleukin-6 regulation. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2020, 318, R296-R310.	0.9	48
502	Cancer-Associated Cachexia: A Systemic Consequence of Cancer Progression. Annual Review of Cancer Biology, 2020, 4, 391-411.	2.3	25
503	Inflammation and Skeletal Muscle Wasting During Cachexia. Frontiers in Physiology, 2020, 11, 597675.	1.3	170

#	Article	IF	Citations
504	Wound Repair, Scar Formation, and Cancer: Converging on Activin. Trends in Molecular Medicine, 2020, 26, 1107-1117.	3.5	32
505	TMEPAI/PMEPA1 Is a Positive Regulator of Skeletal Muscle Mass. Frontiers in Physiology, 2020, 11, 560225.	1.3	5
506	Exploiting common aspects of obesity and cancer cachexia for future therapeutic strategies. Current Opinion in Pharmacology, 2020, 53, 101-116.	1.7	10
507	Therapeutic potential of muscle growth promoters in a stress urinary incontinence model. American Journal of Physiology - Renal Physiology, 2020, 319, F436-F446.	1.3	0
508	Myostatin inhibition promotes fast fibre hypertrophy but causes loss of AMPâ€activated protein kinase signalling and poor exercise tolerance in a model of limbâ€girdle muscular dystrophy R1/2A. Journal of Physiology, 2020, 598, 3927-3939.	1.3	7
509	Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake. , 2020, 10, 785-809.		181
510	The wastingâ€associated metabolite succinate disrupts myogenesis and impairs skeletal muscle regeneration. JCSM Rapid Communications, 2020, 3, 56-69.	0.6	12
511	ACVR2B antagonism as a countermeasure to multiâ€organ perturbations in metastatic colorectal cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1779-1798.	2.9	26
512	Serum Myostatin Predicts the Risk of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Multicenter Study. Cancers, 2020, 12, 3347.	1.7	9
513	A Role for Caveolin-3 in the Pathogenesis of Muscular Dystrophies. International Journal of Molecular Sciences, 2020, 21, 8736.	1.8	31
514	Nutraceuticals and Exercise against Muscle Wasting during Cancer Cachexia. Cells, 2020, 9, 2536.	1.8	23
515	High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlo	0.4	9
516	Cancer Cachexia: Definition, Staging, and Emerging Treatments . Cancer Management and Research, 2020, Volume 12, 5597-5605.	0.9	115
517	Activin A: an emerging target for improving cancer treatment?. Expert Opinion on Therapeutic Targets, 2020, 24, 985-996.	1.5	20
518	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 2272-2289.	2.9	92
519	Alternative signaling pathways from IGF1 or insulin to AKT activation and FOXO1 nuclear efflux in adult skeletal muscle fibers. Journal of Biological Chemistry, 2020, 295, 15292-15306.	1.6	8
520	Systemic blockade of ACVR2B ligands attenuates muscle wasting in ischemic heart failure without compromising cardiac function. FASEB Journal, 2020, 34, 9911-9924.	0.2	6
521	Leucine and Its Importance for Cell Signalling Pathways in Cancer Cachexia-Induced Muscle Wasting. , 0, , .		2

#	Article	IF	Citations
522	Activin A affects feeding by promoting the inner diameter and muscle development of the pharynx and oesophagus in zebrafish (Danio rerio) larvae. Journal of Fish Biology, 2020, 97, 1624-1631.	0.7	2
523	Cancer-Associated Muscle Wastingâ€"Candidate Mechanisms and Molecular Pathways. International Journal of Molecular Sciences, 2020, 21, 9268.	1.8	20
524	Marked Increased Production of Acute Phase Reactants by Skeletal Muscle during Cancer Cachexia. Cancers, 2020, 12, 3221.	1.7	7
525	Cancer Cachexia Induces Preferential Skeletal Muscle Myosin Loss When Combined With Denervation. Frontiers in Physiology, 2020, 11, 445.	1.3	16
526	An elevated neutrophil-to-lymphocyte ratio associates with weight loss and cachexia in cancer. Scientific Reports, 2020, 10, 7535.	1.6	49
527	Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3. Pharmacological Research, 2020, 158, 104871.	3.1	25
528	A paracrine activin Aâ€"mDia2 axis promotes squamous carcinogenesis via fibroblast reprogramming. EMBO Molecular Medicine, 2020, 12, e11466.	3.3	40
529	Differentiation of Murine C2C12 Myoblasts Strongly Reduces the Effects of Myostatin on Intracellular Signaling. Biomolecules, 2020, 10, 695.	1.8	18
530	A signaling hub of insulin receptor, dystrophin glycoprotein complex and plakoglobin regulates muscle size. Nature Communications, 2020, 11, 1381.	5.8	33
531	Management of Cancer Cachexia: Attempting to Develop New Pharmacological Agents for New Effective Therapeutic Options. Frontiers in Oncology, 2020, 10, 298.	1.3	63
532	Exercise-Mediated Lowering of Glutamine Availability Suppresses Tumor Growth and Attenuates Muscle Wasting. IScience, 2020, 23, 100978.	1.9	10
533	<scp>USP</scp> 1 deubiquitinates Akt to inhibit <scp>PI</scp> 3Kâ€Aktâ€FoxO signaling in muscle during prolonged starvation. EMBO Reports, 2020, 21, e48791.	2.0	64
534	Understanding cachexia in the context of metastatic progression. Nature Reviews Cancer, 2020, 20, 274-284.	12.8	124
535	Magnolol inhibits myotube atrophy induced by cancer cachexia through myostatin signaling pathway in vitro. Journal of Natural Medicines, 2020, 74, 741-749.	1.1	6
536	Oncogene-Induced Senescence Limits the Progression of Pancreatic Neoplasia through Production of Activin A. Cancer Research, 2020, 80, 3359-3371.	0.4	20
537	Muscle NAD+ depletion and Serpina3n as molecular determinants of murine cancer cachexiaâ€"the effects of blocking myostatin and activins. Molecular Metabolism, 2020, 41, 101046.	3.0	21
538	Regulatory Role of the Transcription Factor Twist1 in Cancer-Associated Muscle Cachexia. Frontiers in Physiology, 2020, 11, 662.	1.3	4
539	Mathematical Model of Muscle Wasting in Cancer Cachexia. Journal of Clinical Medicine, 2020, 9, 2029.	1.0	8

#	Article	IF	Citations
540	Targeting all transforming growth factor-Î² isoforms with an Fc chimeric receptor impairs tumor growth and angiogenesis of oral squamous cell cancer. Journal of Biological Chemistry, 2020, 295, 12559-12572.	1.6	30
541	Emerging Strategies Targeting Catabolic Muscle Stress Relief. International Journal of Molecular Sciences, 2020, 21, 4681.	1.8	9
542	Signaling Pathways That Control Muscle Mass. International Journal of Molecular Sciences, 2020, 21, 4759.	1.8	104
543	Cisplatin-Induced Skeletal Muscle Dysfunction: Mechanisms and Counteracting Therapeutic Strategies. International Journal of Molecular Sciences, 2020, 21, 1242.	1.8	75
544	Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1873, 188359.	3.3	53
545	The Emerging Role of MicroRNAs and Other Non-Coding RNAs in Cancer Cachexia. Cancers, 2020, 12, 1004.	1.7	30
546	The clinical relevance and mechanism of skeletal muscle wasting. Clinical Nutrition, 2021, 40, 27-37.	2.3	24
547	ActivinA activates Notch1-Shh signaling to regulate proliferation in C2C12 skeletal muscle cells. Molecular and Cellular Endocrinology, 2021, 519, 111055.	1.6	8
548	Inhibition of the activin receptor signaling pathway: A novel intervention against osteosarcoma. Cancer Medicine, 2021, 10, 286-296.	1.3	3
549	Development of functionalized peptides for efficient inhibition of myostatin by selective photooxygenation. Organic and Biomolecular Chemistry, 2021, 19, 199-207.	1.5	2
550	Myostatin deficiency not only prevents muscle wasting but also improves survival in septic mice. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E150-E159.	1.8	15
551	Receptor binding competition: A paradigm for regulating TGF-Î² family action. Cytokine and Growth Factor Reviews, 2021, 57, 39-54.	3.2	49
552	Myokines mediate the cross talk between skeletal muscle and other organs. Journal of Cellular Physiology, 2021, 236, 2393-2412.	2.0	74
553	Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia. Oncogenesis, 2021, 10, 1.	2.1	75
554	Ubiquitin Ligases at the Heart of Skeletal Muscle Atrophy Control. Molecules, 2021, 26, 407.	1.7	31
555	Breakdown of Filamentous Myofibrils by the UPSâ€"Step by Step. Biomolecules, 2021, 11, 110.	1.8	13
556	Master Regulators of Muscle Atrophy: Role of Costamere Components. Cells, 2021, 10, 61.	1.8	17
557	GDF15/GFRAL Pathway as a Metabolic Signature for Cachexia in Patients with Cancer. Journal of Cancer, 2021, 12, 1125-1132.	1.2	32

#	Article	IF	Citations
558	Muscle Tissue in Hypothyroidism and Hyperthyroidism. , 2021, , 209-219.		0
559	Exercise Training as Therapeutic Approach in Cancer Cachexia: A Review of Potential Anti-inflammatory Effect on Muscle Wasting. Frontiers in Physiology, 2020, 11, 570170.	1.3	18
560	Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments. Cells, 2021, 10, 516.	1.8	14
561	Exosomal microRNAs in cancer-related sarcopenia: Tumor-derived exosomal microRNAs in muscle atrophy. Experimental Biology and Medicine, 2021, 246, 1156-1166.	1.1	4
562	ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders. Journal of Clinical Investigation, 2021, 131, .	3.9	19
563	Muscle follistatin gene delivery increases muscle protein synthesis independent of periodical physical inactivity and fasting. FASEB Journal, 2021, 35, e21387.	0.2	9
565	Phenotypic features of cancer cachexiaâ€related loss of skeletal muscle mass and function: lessons from human and animal studies. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 252-273.	2.9	43
566	Resistance Trainingâ€™s Ability to Prevent Cancer-induced Muscle Atrophy Extends Anabolic Stimulus. Medicine and Science in Sports and Exercise, 2021, 53, 1572-1582.	0.2	10
567	Mediators and clinical treatment for cancer cachexia: a systematic review. JCSM Rapid Communications, 2021, 4, 166-186.	0.6	19
568	Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success. Cells, 2021, 10, 533.	1.8	19
569	Drugs for the Treatment of Muscle Atrophy. , 0, , .		2
570	Clinical Impact of Sarcopenia on Gastrointestinal Tumors. Gastrointestinal Disorders, 2021, 3, 51-60.	0.4	3
571	Different definitions of sarcopenia and mortality in cancer: A meta-analysis. Osteoporosis and Sarcopenia, 2021, 7, S34-S38.	0.7	13
572	Sarcopenia and mortality in cancer: A meta-analysis. Osteoporosis and Sarcopenia, 2021, 7, S28-S33.	0.7	49
573	Molecular Mechanisms, Therapeutic Targets and Pharmacological Interventions: An Update. , 0, , .		0
574	Antagonistic control of myofiber size and muscle protein quality control by the ubiquitin ligase UBR4 during aging. Nature Communications, 2021, 12, 1418.	5.8	30
575	Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities. Expert Opinion on Investigational Drugs, 2021, 30, 519-527.	1.9	14
576	Biomarkers for Cancer Cachexia: A Mini Review. International Journal of Molecular Sciences, 2021, 22, 4501.	1.8	26

#	Article	IF	Citations
577	A deep analysis of the proteomic and phosphoproteomic alterations that occur in skeletal muscle after the onset of immobilization. Journal of Physiology, 2021, 599, 2887-2906.	1.3	13
578	Cancer cachexia: molecular mechanism and pharmacological management. Biochemical Journal, 2021, 478, 1663-1688.	1.7	18
579	Age Trends in Growth and Differentiation Factor-11 and Myostatin Levels in Healthy Men, and Differential Response to Testosterone, Measured Using Liquid Chromatographyâ€"Tandem Mass Spectrometry. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 763-769.	1.7	12
580	Systemic administration of monovalent follistatin-like 3-Fc-fusion protein increases muscle mass in mice. IScience, 2021, 24, 102488.	1.9	12
581	Awareness of Cancer-Related Malnutrition and Its Management: Analysis of the Results From a Survey Conducted Among Medical Oncologists. Frontiers in Oncology, 2021, 11, 682999.	1.3	33
582	Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction. Journal of Clinical Investigation, 2021, 131, .	3.9	55
583	Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs. Journal of Clinical Investigation, 2021, 131, .	3.9	34
584	Distinct glycolytic pathway regulation in liver, tumour and skeletal muscle of mice with cancer cachexia. Cell Biochemistry and Function, 2021, 39, 802-812.	1.4	6
585	Apocynin prevents cigarette smokingâ€induced loss of skeletal muscle mass and function in mice by preserving proteostatic signalling. British Journal of Pharmacology, 2021, 178, 3049-3066.	2.7	9
586	Tumors overcome the action of the wasting factor ImpL2 by locally elevating Wnt/Wingless. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	23
587	Dual Roles of the Activin Signaling Pathway in Pancreatic Cancer. Biomedicines, 2021, 9, 821.	1.4	5
588	Targeting cancer via ribosome biogenesis: the cachexia perspective. Cellular and Molecular Life Sciences, 2021, 78, 5775-5787.	2.4	9
589	Amiloride ameliorates muscle wasting in cancer cachexia through inhibiting tumor-derived exosome release. Skeletal Muscle, 2021, 11, 17.	1.9	26
590	Coordination of tumor growth and host wasting by tumor-derived Upd3. Cell Reports, 2021, 36, 109553.	2.9	35
591	Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia. Science Translational Medicine, 2021, 13, .	5.8	58
592	Metabolic Remodeling in Skeletal Muscle Atrophy as a Therapeutic Target. Metabolites, 2021, 11, 517.	1.3	6
593	Mesenchymal Stem Cell-Derived Exosomes Protect Muscle Loss by miR-145-5p Activity Targeting Activin A Receptors. Cells, 2021, 10, 2169.	1.8	14
594	Strategic structureâ€"activity relationship study on a follistatin-derived myostatin inhibitory peptide. Bioorganic and Medicinal Chemistry Letters, 2021, 46, 128163.	1.0	4

#	Article	IF	Citations
595	UBE2L3, a Partner of MuRF1/TRIM63, Is Involved in the Degradation of Myofibrillar Actin and Myosin. Cells, 2021, 10, 1974.	1.8	9
596	Principles of the activin receptor signaling pathway and its inhibition. Cytokine and Growth Factor Reviews, 2021, 60, 1-17.	3.2	24
597	Skeletal Muscle Deconditioning in Breast Cancer Patients Undergoing Chemotherapy: Current Knowledge and Insights From Other Cancers. Frontiers in Cell and Developmental Biology, 2021, 9, 719643.	1.8	19
598	A Novel Splice Variant of Human TGF-Î² Type II Receptor Encodes a Soluble Protein and Its Fc-Tagged Version Prevents Liver Fibrosis in vivo. Frontiers in Cell and Developmental Biology, 2021, 9, 690397.	1.8	2
599	Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs. Endocrine Reviews, 2022, 43, 329-365.	8.9	24
601	Nutritional intervention for cancer sarcopenia. Annals of Musculoskeletal Medicine, 2021, , 001-004.	0.6	1
602	Myotonic Dystrophy and Developmental Regulation of RNA Processing. , 2018, 8, 509-553.		26
603	Glutamine and Myostatin Expression in Muscle Wasting. , 2015, , 513-526.		1
604	Molecular characterization of the myostatin gene and its regulation on muscle growth in Yesso scallop Patinopecten yessoensis. Aquaculture, 2020, 520, 734982.	1.7	11
605	Resistance and tolerance defenses in cancer: Lessons from infectious diseases. Seminars in Immunology, 2017, 32, 54-61.	2.7	9
606	Peptideâ€2 from mouse myostatin precursor protein alleviates muscle wasting in cancerâ€associated cachexia. Cancer Science, 2020, 111, 2954-2964.	1.7	8
607	The Role of IL-6 and Myogenic Transcription Factors in Skeletal Muscle Wasting and Dysfunction Due to Cancer Cachexia. World Journal of Cancer Research, 2013, 1, 15-23.	0.2	1
608	<i>Drosophila</i> Activin signaling promotes muscle growth through InR/dTORC1 dependent and independent processes. Development (Cambridge), 2021, 148, .	1.2	11
609	Highly Specific Detection of Myostatin Prodomain by an Immunoradiometric Sandwich Assay in Serum of Healthy Individuals and Patients. PLoS ONE, 2013, 8, e80454.	1.1	24
610	Depletion of White Adipose Tissue in Cancer Cachexia Syndrome Is Associated with Inflammatory Signaling and Disrupted Circadian Regulation. PLoS ONE, 2014, 9, e92966.	1.1	69
611	Activin B Antagonizes RhoA Signaling to Stimulate Mesenchymal Morphology and Invasiveness of Clear Cell Renal Cell Carcinomas. PLoS ONE, 2014, 9, e111276.	1.1	13
612	Distinct Behaviour of Sorafenib in Experimental Cachexia-Inducing Tumours: The Role of STAT3. PLoS ONE, 2014, 9, e113931.	1.1	24
613	TGF-Î² Blockade Reduces Mortality and Metabolic Changes in a Validated Murine Model of Pancreatic Cancer Cachexia. PLoS ONE, 2015, 10, e0132786.	1.1	66

#	Article	IF	Citations
614	Supplementation of Magnolol Attenuates Skeletal Muscle Atrophy in Bladder Cancer-Bearing Mice Undergoing Chemotherapy via Suppression of FoxO3 Activation and Induction of IGF-1. PLoS ONE, 2015, 10, e0143594.	1.1	33
615	Expression of CCAAT/Enhancer Binding Protein Beta in Muscle Satellite Cells Inhibits Myogenesis in Cancer Cachexia. PLoS ONE, 2015, 10, e0145583.	1.1	29
616	Low skeletal muscle mass is associated with increased hospital expenditure in patients undergoing cancer surgery of the alimentary tract. PLoS ONE, 2017, 12, e0186547.	1.1	38
617	p38Î² MAPK mediates ULK1-dependent induction of autophagy in skeletal muscle of tumor-bearing mice. Cell Stress, 2018, 2, 311-324.	1.4	30
618	The Role of Systemic Inflammation in Cancerâ€Associated Muscle Wasting and Rationale for Exercise as a Therapeutic Intervention. JCSM Clinical Reports, 2018, 3, 1-19.	0.5	35
619	Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging, 2012, 4, 133-143.	1.4	72
620	Prognostic value of follistatin-like 3 in human invasive breast cancer. Oncotarget, 2017, 8, 42189-42197.	0.8	11
621	Proteomic profiling of skeletal and cardiac muscle in cancer cachexia: alterations in sarcomeric and mitochondrial protein expression. Oncotarget, 2018, 9, 22001-22022.	0.8	40
622	Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle. Oncotarget, 2015, 6, 3043-3054.	0.8	38
623	Combined administration of fucoidan ameliorates tumor and chemotherapy-induced skeletal muscle atrophy in bladder cancer-bearing mice. Oncotarget, 2016, 7, 51608-51618.	0.8	49
624	The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma. Clinical and Molecular Hepatology, 2020, 26, 492-505.	4.5	39
625	The Effect of Loop Diuretics on Sarcopenia and Long-Term Prognosis in Patients with Refractory Hepatic Ascites Treated with Tolvaptan. Open Journal of Gastroenterology, 2018, 08, 201-208.	0.1	1
626	Relationship between cachexia and perineural invasion in pancreatic adenocarcinoma. World Journal of Gastrointestinal Oncology, 2019, 11, 1126-1140.	0.8	3
627	Cellular Degradation Machineries in Age-Related Loss of Muscle Mass (Sarcopenia). , 0, , .		6
628	Plasma and tissue free amino acid profiles and their concentration correlation in patients with lung cancer. Asia Pacific Journal of Clinical Nutrition, 2014, 23, 429-36.	0.3	27
629	Myofiber-specific TEAD1 overexpression drives satellite cell hyperplasia and counters pathological effects of dystrophin deficiency. ELife, 2016, 5, .	2.8	14
630	Cancer Cachexia. UNIPA Springer Series, 2021, , 327-347.	0.1	0
631	Prospects of 3D Bioprinting as a Possible Treatment for Cancer Cachexia. Journal of Clinical and Experimental Investigations, 2021, 12, em00783.	0.1	0

#	Article	IF	Citations
632	Drug flexes muscle against cancer. Nature, 0, , .	13.7	0
634	Anorexiaâ€“cachexia. , 2012, , 82-96.		0
635	Cancer Cachexia. , 2014, , 620-625.		0
636	Medicinal Chemistry of Mid-sized Molecules on Biologically Active Peptides. Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 2015, 73, 737-748.	0.0	0
637	The COPD Pipeline XXXII. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2016, 3, 688-692.	0.5	1
638	Progress in Mechanism of Muscle Wasting in Cachexia. World Journal of Cancer Research, 2016, 06, 43-48.	0.1	0
639	The Effects of Long-term Exercise on the Expression of SPARC and OSM in Colon Cancer-induced Mice. Exercise Science, 2016, 25, 76-84.	0.1	1
640	Skeletal Muscles Do not Undergo Apoptosis During Either Atrophy or Programmed Cell Death. Journal of Cell Signaling, 2017, 02, .	0.3	0
642	Pancreatic Cancer Cachexia: Current Concepts and Clinical Management. , 0, , .		1
643	Evaluation of a Surface Electromyogram Frequency Analysis Method for Muscle Fiber Evaluation in the Gastrocnemius Muscle. Rigakuryoho Kagaku, 2018, 33, 779-782.	0.0	0
647	Higher tumor mass and lower adipose mass are associated with colonâ€‘26 adenocarcinomaâ€‘induced cachexia in male, female and ovariectomized mice. Oncology Reports, 2019, 41, 2909-2918.	1.2	5
651	Prognostic Implications of Physical Frailty and Sarcopenia Pre and Post Transplantation. , 2020, , 55-76.		0
652	Enzymatic Stability of Myostatin Inhibitory 16-mer Peptides. Chemical and Pharmaceutical Bulletin, 2020, 68, 512-515.	0.6	3
655	Selective Myostatin Inhibition Spares Sublesional Muscle Mass and Myopenia-Related Dysfunction after Severe Spinal Cord Contusion in Mice. Journal of Neurotrauma, 2021, 38, 3440-3455.	1.7	4
656	L-carnitine ameliorates the muscle wasting of cancer cachexia through the AKT/FOXO3a/MaFbx axis. Nutrition and Metabolism, 2021, 18, 98.	1.3	13
657	Hypothalamic Obesity and Wasting Syndromes. Contemporary Endocrinology, 2021, , 235-280.	0.3	0
658	Acylated and Unacylated Ghrelin Relieve Cancer Cachexia in Mice through Multiple Mechanisms. Chinese Journal of Physiology, 2020, 63, 195-203.	0.4	5
661	Activation of Aktâ€“mTORC1 signalling reverts cancerâ€dependent muscle wasting. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 648-661.	2.9	35

#	Article	IF	Citations
663	Muscle abnormalities in osteogenesis imperfecta. Journal of Musculoskeletal Neuronal Interactions, 2017, 17, 1-7.	0.1	31
664	Prostate cancer reduces endurance exercise capacity in association with reductions in cardiac and skeletal muscle mass in the rat. American Journal of Cancer Research, 2017, 7, 2566-2576.	1.4	7
665	Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. JCSM Rapid Communications, 2019, 2, .	0.6	19
666	The Role of Systemic Inflammation in Cancer-Associated Muscle Wasting and Rationale for Exercise as a Therapeutic Intervention. JCSM Clinical Reports, 2018, 3, .	0.5	23
667	A large-scale transgenic RNAi screen identifies transcription factors that modulate myofiber size in Drosophila. PLoS Genetics, 2021, 17, e1009926.	1.5	11
668	Integrated genomic and proteomic analyses identify stimulus-dependent molecular changes associated with distinct modes of skeletal muscle atrophy. Cell Reports, 2021, 37, 109971.	2.9	32
669	Current Thoughts of Notchâ€™s Role in Myoblast Regulation and Muscle-Associated Disease. International Journal of Environmental Research and Public Health, 2021, 18, 12558.	1.2	8
670	Cancerâ€"A Major Cardiac Comorbidity With Implications on Cardiovascular Metabolism. Frontiers in Physiology, 2021, 12, 729713.	1.3	18
671	Downregulation of miR-29c promotes muscle wasting by modulating the activity of leukemia inhibitory factor in lung cancer cachexia. Cancer Cell International, 2021, 21, 627.	1.8	6
672	Autophagy in Cardiac Physiology and Pathology. , 2022, , 61-86.		0
673	FOXO1 cooperates with C/EBPÎ´ and ATF4 to regulate skeletal muscle atrophy transcriptional program during fasting. FASEB Journal, 2022, 36, e22152.	0.2	22
674	Development of ovarian tumour causes significant loss of muscle and adipose tissue: a novel mouse model for cancer cachexia study. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1289-1301.	2.9	17
675	Metabolomics and its Applications in Cancer Cachexia. Frontiers in Molecular Biosciences, 2022, 9, 789889.	1.6	11
676	Cancer-related fibrosis: Prevention or treatment? â€“ A descriptive review. Journal of Dr NTR University of Health Sciences, 2021, 10, 222.	0.0	1
677	Emerging signaling mediators in the anorexiaâ€“cachexia syndrome of cancer. Trends in Cancer, 2022, 8, 397-403.	3.8	23
678	Extreme leanness, lower skeletal muscle quality, and loss of muscle mass during treatment are predictors of poor prognosis in cervical cancer treated with concurrent chemoradiation therapy. International Journal of Clinical Oncology, 2022, 27, 983-991.	1.0	7
680	Development of Myostatin Inhibitory <scp>d</scp>-Peptides to Enhance the Potency, Increasing Skeletal Muscle Mass in Mice. ACS Medicinal Chemistry Letters, 2022, 13, 492-498.	1.3	9
681	Iron supplementation is sufficient to rescue skeletal muscle mass and function in cancer cachexia. EMBO Reports, 2022, 23, e53746.	2.0	26

#	Article	IF	Citations
682	Cardiac Complications: The Understudied Aspect of Cancer Cachexia. Cardiovascular Toxicology, 2022, 22, 254-267.	1.1	2
683	Chemotherapy-induced cachexia and model-informed dosing to preserve lean mass in cancer treatment. PLoS Computational Biology, 2022, 18, e1009505.	1.5	4
684	Review of Mechanisms and Treatment of Cancer-Induced Cardiac Cachexia. Cells, 2022, 11, 1040.	1.8	5
685	Activin A Causes Muscle Atrophy through MEF2C-Dependent Impaired Myogenesis. Cells, 2022, 11, 1119.	1.8	6
686	Sarcopenia in Children with Solid Organ Tumors: An Instrumental Era. Cells, 2022, 11, 1278.	1.8	7
687	Apelin Resistance Contributes to Muscle Loss during Cancer Cachexia in Mice. Cancers, 2022, 14, 1814.	1.7	3
688	Understanding the molecular basis of anorexia and tissue wasting in cancer cachexia. Experimental and Molecular Medicine, 2022, 54, 426-432.	3.2	27
689	Rationally designed nanoparticle delivery of Cas9 ribonucleoprotein for effective gene editing. Journal of Controlled Release, 2022, 345, 108-119.	4.8	9
690	Nutrition challenges of cancer cachexia. Journal of Parenteral and Enteral Nutrition, 2021, 45, 16-25.	1.3	12
691	Weight Loss in Cancer Patients Correlates With p38Î² MAPK Activation in Skeletal Muscle. Frontiers in Cell and Developmental Biology, 2021, 9, 784424.	1.8	4
692	Cardiac myocyte intrinsic contractility and calcium handling deficits underlie heart organ dysfunction in murine cancer cachexia. Scientific Reports, 2021, 11, 23627.	1.6	5
693	Muscle wasting in cancer: opportunities and challenges for exercise in clinical cancer trials. JCSM Rapid Communications, 2022, 5, 52-67.	0.6	10
694	MicroRNAs as Potential Biomarkers for Exercise-Based Cancer Rehabilitation in Cancer Survivors. Life, 2021, 11, 1439.	1.1	4
695	Pathological features of tissues and cell populations during cancer cachexia. Cell Regeneration, 2022, 11, 15.	1.1	7
696	ActivinÂA promotes cell proliferation, invasion and migration and predicts poor prognosis in patients with colorectal cancer. Oncology Reports, 2022, 47, .	1.2	3
706	Molecular Mechanisms and Current Treatment Options for Cancer Cachexia. Cancers, 2022, 14, 2107.	1.7	12
707	Tumor cell anabolism and host tissue catabolism-energetic inefficiency during cancer cachexia. Experimental Biology and Medicine, 2022, 247, 713-733.	1.1	5
708	The emerging landscape of exosomal CircRNAs in solid cancers and hematological malignancies. Biomarker Research, 2022, 10, 28.	2.8	9

#	Article	IF	Citations
709	Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 2146-2161.	2.9	31
710	Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension. Scientific Reports, 2022, 12, 7803.	1.6	26
711	The myokine Fibcd1 is an endogenous determinant of myofiber size and mitigates cancer-induced myofiber atrophy. Nature Communications, 2022, 13, 2370.	5.8	14
712	Electroporation of Small Interfering RNAs into Tibialis Anterior Muscles of Mice. Bio-protocol, 2022, 12, .	0.2	0
713	Restoring faith in conservation action: Maintaining wild genetic diversity through the Tasmanian devil insurance program. IScience, 2022, 25, 104474.	1.9	8
714	Peptide Tool-Driven Functional Elucidation of Biomolecules Related to Endocrine System and Metabolism. Chemical and Pharmaceutical Bulletin, 2022, 70, 413-419.	0.6	0
715	Cardiac Remodeling in Cancer-Induced Cachexia: Functional, Structural, and Metabolic Contributors. Cells, 2022, 11, 1931.	1.8	5
716	Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies. Frontiers in Physiology, 0, 13, .	1.3	19
717	Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseases. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	16
718	Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies. Life, 2022, 12, 880.	1.1	1
719	Effect of Sarcopenia on Cancer Survival: A Propensity Score-Matched Population-Based Cohort Study. SSRN Electronic Journal, 0, , .	0.4	0
720	Palliative oncology and palliative care. Molecular Oncology, 2022, 16, 3399-3409.	2.1	3
721	Muscle-to-tumor crosstalk: The effect of exercise-induced myokine on cancer progression. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188761.	3.3	20
722	Evidence for reciprocal network interactions between injured hearts and cancer. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
723	Myostatin: a multifunctional role in human female reproduction and fertility â€“ a short review. Reproductive Biology and Endocrinology, 2022, 20, .	1.4	7
724	Bidirectional roles of skeletal muscle fibro-adipogenic progenitors in homeostasis and disease. Ageing Research Reviews, 2022, 80, 101682.	5.0	19
725	Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model. Cancer Science, 2022, 113, 3547-3557.	1.7	5
726	Blocking ActRIIB and restoring appetite reverses cachexia and improves survival in mice with lung cancer. Nature Communications, 2022, 13, .	5.8	21

#	Article	IF	Citations
727	Cancer cell-derived exosomal miR-425-3p induces white adipocyte atrophy. Adipocyte, 2022, 11, 487-500.	1.3	11
728	Muscular myostatin gene expression and plasma concentrations are decreased in critically ill patients. Critical Care, 2022, 26, .	2.5	0
729	Therapy-Induced Toxicities Associated with the Onset of Cachexia. , 2022, , 139-153.		0
730	Bone-Muscle Crosstalk in Advanced Cancer and Chemotherapy. , 2022, , 155-167.		0
731	Signaling Pathways That Promote Muscle Catabolism in Cachexia. , 2022, , 71-95.		1
732	Cancer Cachexia: Signaling and Transcriptional Regulation of Muscle Catabolic Genes. Cancers, 2022, 14, 4258.	1.7	8
733	Transforming Growth Factor-Beta Signaling in Cancer-Induced Cachexia: From Molecular Pathways to the Clinics. Cells, 2022, 11, 2671.	1.8	11
734	Targeting cancer cachexia: Molecular mechanisms and clinical study. MedComm, 2022, 3, .	3.1	8
735	Cancer cachexia as a multiorgan failure: Reconstruction of the crime scene. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	6
736	Nanoparticleâ€Based Follistatin Messenger RNA Therapy for Reprogramming Metastatic Ovarian Cancer and Ameliorating Cancerâ€Associated Cachexia. Small, 2022, 18, .	5.2	6
737	Nutrition in Pancreatic Cancer. , 2022, , 317-341.		0
738	Understanding Cancer Cachexia and Its Implications in Upper Gastrointestinal Cancers. Current Treatment Options in Oncology, 2022, 23, 1732-1747.	1.3	8
739	Bone morphogenetic proteins, activins, and growth and differentiation factors in tumor immunology and immunotherapy resistance. Frontiers in Immunology, 0, 13, .	2.2	3
741	Does Myocardial Atrophy Represent Anti-Arrhythmic Phenotype?. Biomedicines, 2022, 10, 2819.	1.4	4
743	Exosomal circRNAs: Novel biomarkers and therapeutic targets for gastrointestinal tumors. Biomedicine and Pharmacotherapy, 2023, 157, 114053.	2.5	5
744	Creatine modulates cellular energy metabolism and protects against cancer cachexia-associated muscle wasting. Frontiers in Pharmacology, 0, 13, .	1.6	3
745	Interruption of the long non-coding RNA HOTAIR signaling axis ameliorates chemotherapy-induced cachexia in bladder cancer. Journal of Biomedical Science, 2022, 29, .	2.6	4
746	C188-9, a specific inhibitor of STAT3 signaling, prevents thermal burn-induced skeletal muscle wasting in mice. Frontiers in Pharmacology, 0, 13, .	1.6	1

#	Article	IF	Citations
747	Activin A level is associated with physical function in critically ill patients. Australian Critical Care, 2022, , .	0.6	0
748	Sarcopenia increases the risk of early biliary infection after percutaneous transhepatic biliary stent placement. Frontiers in Oncology, 0, 12, .	1.3	1
749	Mechanism of Skeletal Muscle Atrophy Using a Mice Cancer Cachexia Model. , 2022, , 559-578.		0
750	Exercise Protocols for Counteracting Cancer Cachexia-Related Declines in Muscle Mass and Strength and the Clinical Assessment of Skeletal Muscle. , 2022, , 215-251.		0
751	Progressive development of melanoma-induced cachexia differentially impacts organ systems in mice. Cell Reports, 2023, 42, 111934.	2.9	2
752	Inactivation of myostatin by photooxygenation using functionalized D-peptides. RSC Medicinal Chemistry, 0, , .	1.7	0
753	Inhibiting myostatin signaling partially mitigates structural and functional adaptations to hindlimb suspension in mice. Npj Microgravity, 2023, 9, .	1.9	3
754	Cellular interplay in skeletal muscle regeneration and wasting: insights from animal models. Journal of Cachexia, Sarcopenia and Muscle, 2023, 14, 745-757.	2.9	13
755	The Role of TGF-Î², Activin and Follistatin in Inflammatory Bowel Disease. Gastrointestinal Disorders, 2023, 5, 167-186.	0.4	1
756	A New Signature of Sarcoma Based on the Tumor Microenvironment Benefits Prognostic Prediction. International Journal of Molecular Sciences, 2023, 24, 2961.	1.8	3
757	Evaluation of Associations of Growth Differentiation Factor-11, Growth Differentiation Factor-8, and Their Binding Proteins, Follistatin and Follistatin-Like Protein-3, With Measures of Skeletal Muscle Mass, Muscle Strength, and Physical Function in Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 0, , .	1.7	1
758	Emerging Mechanisms of Skeletal Muscle Homeostasis and Cachexia: The SUMO Perspective. Cells, 2023, 12, 644.	1.8	3
760	COVID-19 in Older Patients: Assessment of Post-COVID-19 Sarcopenia. Biomedicines, 2023, 11, 733.	1.4	0
761	The Impact of Sarcopenia Onset Prior to Cancer Diagnosis on Cancer Survival: A National Population-Based Cohort Study Using Propensity Score Matching. Nutrients, 2023, 15, 1247.	1.7	3
762	Molecular mechanisms of cancer cachexiaâ€related loss of skeletal muscle mass: data analysis from preclinical and clinical studies. Journal of Cachexia, Sarcopenia and Muscle, 2023, 14, 1150-1167.	2.9	16
763	Increasing Skeletal Muscle Mass in Mice by Non-Invasive Intramuscular Delivery of Myostatin Inhibitory Peptide by Iontophoresis. Pharmaceuticals, 2023, 16, 397.	1.7	0
764	Diminished vasculogenesis under inflammatory conditions is mediated by Activin A. Angiogenesis, 0, , .	3.7	1
765	Current advancements in pharmacotherapy for cancer cachexia. Expert Opinion on Pharmacotherapy, 2023, 24, 629-639.	0.9	3

#	Article	IF	Citations
766	The small molecule <scp>ACM</scp>â€001 improves cardiac function in a rat model of severe cancer cachexia. European Journal of Heart Failure, 2023, 25, 673-686.	2.9	4
767	Red blood cell extracellular vesicles deliver therapeutic siRNAs to skeletal muscles for treatment of cancer cachexia. Molecular Therapy, 2023, 31, 1418-1436.	3.7	3
768	A novel orthotopic mouse model replicates human lung cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2023, 14, 1410-1423.	2.9	3
769	Lunar gravity prevents skeletal muscle atrophy but not myofiber type shift in mice. Communications Biology, 2023, 6, .	2.0	1
784	Context-dependent TGFÎ² family signalling in cell fate regulation. Nature Reviews Molecular Cell Biology, 2023, 24, 876-894.	16.1	4